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1
According to the Dutch Cancer Registry, there were 752,133 cancer survivors in the Netherlands 
on January 1, 2016,1 comprising 4.4% of the Dutch population.2 Of these survivors, 417,326 
were female and 3.8% of them were aged < 40 years, resulting in 16,034 female cancer survivors 
of reproductive age.1 These survival rates have been continuously rising due to better screening 
methods for early cancer detection and enhanced treatment modalities, such as chemotherapy 
and radiotherapy.3 Unfortunately, chemotherapy and pelvic radiotherapy might be highly 
gonadotoxic and result in premature ovarian failure/insufficiency, which is defined as amenorrhea 
due to premature depletion of functional ovarian follicles in women < 40 years.4 Consequently, 
these treatments may cause severe morbidities related to estrogen deficiency. These include 
for instance osteoporosis, increased risk of cardiovascular disease and reduced emotional well-
being.5 In addition, these treatments may have a detrimental impact on future fertility, all of 
which will profoundly influence the cancer survivor’s quality of life. The risk of fertility impairment 
increases with patient age and is associated with the type, dose and duration of chemotherapy 
and radiotherapy administered.6,7 
In order to spare young female cancer patients the deleterious effects of gonadotoxic 
therapies, much effort has been devoted to preserving fertility. The currently available fertility 
preservation options for women who receive chemotherapy, whether or not in combination with 
pelvic radiotherapy, are cryopreservation of either embryos, oocytes, or ovarian tissue.8 Although 
cryopreservation of embryos and oocytes are at present the only established options, both 
methods have several disadvantages. Firstly, they require hormonal stimulation for optimal oocyte 
harvesting. As a result, these methods cannot be applied to prepubescent girls nor women who 
lack sufficient time to undergo oocyte retrievals. Secondly, normal ovarian function cannot be 
restored. Cryopreservation and subsequent autotransplantation of ovarian tissue may overcome 
these limitations. 
Cryopreservation and autotransplantation of ovarian tissue
Cryopreservation of ovarian tissue is the only option available for prepubescent girls and patients 
who require immediate gonadotoxic treatment because of aggressive malignancies.8 Furthermore, 
it is the only fertility preservation method by which ovarian function can be reinstated. To become 
eligible for ovarian tissue cryopreservation, several selection criteria should be met. These 
selection criteria include among others: age < 35 years, a good ovarian reserve, a realistic chance 
of survival, and a high risk of premature ovarian insufficiency (> 50%).9,10 The selection criteria 
are indicative. For instance, cryopreservation of ovarian tissue has also been performed in patients 
who were slightly older.11-13 
Preferentially, ovarian tissue is cryopreserved before the start of gonadotoxic treatment. 
After laparoscopic unilateral oophorectomy, the ovary is transferred to the laboratory. At the 
laboratory, the ovaries are cut into halves and the medulla is removed. The remaining cortex 








































12  |  Chapter 1
approximately 5-10 mm in diameter. Following this, the cortical ovarian fragments are frozen, 
usually according to a slow-freezing procedure, and stored in liquid nitrogen at -196 °C.12 When 
the patient experiences premature ovarian failure due to the anticancer treatment and wishes to 
conceive, the cortical ovarian strips can be thawed and transplanted back to the remaining ovary 
or a peritoneal window (orthotopic transplantation), or to the abdominal wall or the forearm 
(heterotopic transplantation).14 The first case of successful orthotopic autotransplantation in terms 
of resumption of menses was reported in 2001,15 followed by the first live birth in 2004.16 Until 
now, more than 86 live births have been reported following autotransplantation of ovarian tissue, 
either by spontaneous conception or by in vitro fertilization.17 Restoration of ovarian activity has 
been established in 93% of cases.14 
Experimental nature 
Because of these promising results, some scientists now advocate that autotransplantation of 
frozen-thawed ovarian tissue should no longer be considered experimental.18,19 Nevertheless, the 
American Society for Reproductive Medicine (ASRM) has not yet acknowledged this procedure.20 
The Dutch National Health Care Institute shares the position of the ASRM. This institute 
recently sent a letter to the Minister of Health, Welfare and Sport to point out that ovarian 
tissue autotransplantation is not in accordance with the current state of medical science.21 The 
underlying reason for this is twofold: firstly, the efficiency of ovarian tissue autotransplantation 
remains unclear, as pregnancies may occur in the setting of premature ovarian insufficiency 
and ovarian function may resume after chemotherapy, and secondly, its safety has not been 
determined for certain types of cancer at risk of ovarian involvement. 
Safety concerns with ovarian tissue autotransplantation
The safety of ovarian tissue autotransplantation cannot be ensured, as it has not yet been possible 
to rule out the presence of malignant cells in the cortical ovarian tissues that are transplanted. 
This shortcoming is attributable to the fact that after examination by the currently available 
tumor detection methods (i.e. histology/immunohistochemistry, PCR and xenotransplantation) 
the cortical ovarian tissues can no longer be used for transplantation to the patient. As a result, 
the current tumor detection approach includes assessment of only one or two cortical ovarian 
fragments that are not transplanted, whereas cortical ovarian tissue fragments that are placed 
back remain unchecked.22 Autotransplantation of ovarian tissue thus entails a risk of reimplanting 
malignant cells in the recipient. 
Several studies have found that the risk of reintroducing cancer varies widely among various 
tumor types, with the highest and lowest risk for leukemia and lymphoma, respectively.7,23,24 The 
results presented in these studies were mainly based on histology, PCR and xenotransplantation 
tests that were performed on single ovarian tissue fragments. These reports are valuable with 
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1
transplantation of ovarian tissue. For instance, they showed that there is a genuine risk of 
reimplanting leukemic cells following ovarian tissue autotransplantation, since PCR tests 
frequently showed positive molecular markers in ovarian tissues.25-27 On the other hand, in patients 
with lymphoma the risk of reimplanting malignant cells may be underestimated, as evaluating 
a randomly selected ovarian tissue fragment does not necessarily eliminate the possibility that 
micrometastases are present in the strips that are ultimately transplanted.22,28,29 
Evaluation of the current tumor detection approach
In order to determine whether examining cortical ovarian strips that will not be transplanted 
can accurately predict the absence of tumor cells in the ovarian tissue that will be transplanted, 
we must understand the localization and morphology of metastatic disease in the ovary. Figure 
1 illustrates the different morphological features of disseminated tumor cells in ovarian tissues. 
For example, if tumor cells are homogenously scattered in the ovarian parenchyma (Figure 1a), 
examining one or two cortical ovarian strips will suffice to determine the presence of tumor cells 
in the actual ovarian autografts. On the other hand, if tumor cells are restricted to a relatively 
small region in the ovarian cortex (Figure 1b and Figure 1c), this approach could lead to an 
incorrect diagnosis. Then, cortical ovarian strips that are examined might be devoid of tumor 
cells, whereas cortical ovarian tissues that are transplanted could harbor a metastasis, potentially 
causing recurrent disease. 
Figure 1. Morphological features of disseminated tumor cells within ovarian tissues 
Three examples are shown: (a) diffuse seeding without any discernable pattern, (b) multiple distinct nodules 
separated by uninvolved ovarian tissue and (c) a solitary metastasis. The current tumor detection approach 
can be considered inadequate if disseminated tumor cells manifest as a solitary metastasis or multiple distinct 
nodules within ovarian tissues. In those cases, the absence of metastatic disease in the remaining ovarian 
autografts cannot be guaranteed when the results of testing one fragment are negative for the presence 
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Morphology and localization of ovarian metastases
A detailed review of the literature on the morphology and localization of ovarian metastases 
derived from primary neoplasms in which cryopreservation of ovarian tissue is performed, is 
summarized below.
Breast cancer
Breast cancer is the most commonly diagnosed malignancy in women. Approximately 7% of 
cases diagnosed in Western Europe and the United States are younger than 40 years of age.31-33 
The reported prevalence of ovarian metastases in breast cancer patients ranges from 13-47% 
(Table 1).23,34 The majority of these women are diagnosed with advanced breast cancer.35-38 With 
respect to histological subtype, lobular breast carcinomas are more likely to invade the ovary 
than ductal carcinomas.39,40 Kasilag et al. examined 23 premenopausal patients with ovarian 
metastases.38 Four of these cases had diffuse seeding with no discernable pattern, 11 cases had 
hilar involvement, and one case had a mixed pattern. The remaining seven cases had involvement 
at the ovarian surface. Gagnon et al. examined 59 ovarian metastases derived primarily from 
advanced breast tumors.41 Up to one-third of the ovarian tumors were <1 mm in diameter, and 
typical Indian-file and/or ductal patterns were identified in 75% of cases. In 10% single tumor 
cells were seen. 
 
Cervical cancer
Cervical cancer is the second most commonly diagnosed cancer in women in developing countries 
and the seventh most common cancer in developed countries.42 More than one-fourth of women 
with cervical cancer are of reproductive age.43 Metastases from the cervix to the ovary are present 
in up to 4% of premenopausal women with FIGO stage Ia-IIb cancer,23,44 and are more prevalent 
in adenocarcinoma than in squamous cell carcinoma.45-47 Strikingly, Natsume et al. reported that 
14% of patients with stage Ib and stage II cervical adenocarcinoma have ovarian metastases 
(Table 1).47 The two cases described showed lymphovascular invasion and in one of these two 
cases the pelvic lymph nodes appeared to be involved. Lymphatic spread may be a plausible 
route for ovarian metastases, as metastases are frequently found in the presence of lymphatic 
permeation.44,48 The finding of metastatic lesions in the hilus of two patients with stage IIb 
adenocarcinoma and nodal involvement supports this hypothesis.49 In addition to localization in 
the ovarian hilus, microscopic metastases can also manifest in the ovarian cortex with histological 
features similar to the endocervical tumor.45,50 
Endometrial cancer
Endometrial cancer is the most common malignancy in the female genital tract in Western 
countries. It is usually diagnosed in elderly women, although approximately 5% of cases appear 
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1
endocrine therapy if an absolutely certain diagnosis of an early-stage well-differentiated 
carcinoma is made.53,54 Ovarian involvement occurs in 2-42% of young women with FIGO stage 
I-IV endometrial cancer (Table 1).23,55-58 Bilateral ovarian involvement, a multi-nodular growth 
pattern, surface implants, and prominent lymphovascular permeation within and/or adjacent to 
the ovary should raise suspicion of a metastasis rather than a primary ovarian malignancy.39,58
Colorectal cancer
With respect to colorectal cancer, autotransplantation of frozen-thawed ovarian tissue was 
performed in a 28-year-old patient with invasive anal carcinoma.59 In this patient, serial sections 
of six ovarian specimens measuring 2 mm in diameter revealed no malignant cells. Overall, the 
percentage of ovaries containing bowel tumor cells is approximately 3%, but can reach 33% 
among premenopausal women (Table 1).60 The most common microscopic findings are tall 
columnar cells, dirty or segmental necrosis, and a ‘garland-like’ growth pattern.39,61
Leukemia
Leukemia is the most common hematological cancer among young girls and adolescent 
females40 and can be classified into four subgroups: acute lymphoblastic leukemia (ALL), chronic 
lymphoblastic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia 
(CML). Because PCR tests have consistently yielded positive results for the presence of a disease-
specific molecular marker in cortical ovarian strips and xenotransplantation into nude mice has 
induced tumors, autotransplanting ovarian tissue obtained from leukemia patients is currently 
considered too dangerous.26,27 The likelihood of ovarian metastases occurring during the disease 
course of leukemia is generally up to 62% (Table 1),23 and differs between the various subtypes. 
For example, an analysis of 4728 autopsy reports found ovarian metastases in 41-50% of patients 
with ALL, 21-30% of patients with CLL or AML, and 11-20% of patients with CML.62 However, 
few studies have examined the precise location at which the leukemic cells are trapped within 
the ovary, although Reid and co-workers reported a large mass of leukemic cells in the ovarian 
medullas of a one-year-old girl with AML and a nine-year-old girl with ALL.63 
Lymphoma
Bittinger et al. emphasized the need for a technique that can examine every cortical ovarian 
strip used for transplantation purposes.29 They examined two 10-mm ovarian fragments of one 
ovary obtained from a patient with stage IIIb Hodgkin’s lymphoma. Surprisingly, conspicuous 
malignant cells were found in one fragment, whereas the other fragment was completely devoid 
of tumor cells. In an autopsy study, Kyono et al. found ovarian metastases in 13% of lymphoma 
patients, although the stage of their disease was not specified (Table 1).64 Lastly, Monterroso et al. 
described eighteen patients under the age of 40 with advanced-stage malignant lymphoma and 








































16  |  Chapter 1
cells consistent with aggressive Burkitt’s type lymphoma and were distributed throughout the 
ovarian parenchyma. In addition, some cells were arranged in an Indian-file pattern and were 
more prominent in the periphery of the ovarian cortex. 
Bone and soft tissue tumors
Osteosarcoma, Ewing’s sarcoma, and chondrosarcoma are the most prevalent bone cancers in 
children and young adults.66-68 Among soft tissue tumors, rhabdomyosarcoma is the most common 
form and is often diagnosed in early childhood.69 Although bone tumors rarely metastasize to 
the ovaries, several cases have been reported. For example, a 23-year-old woman with a history 
of osteosarcoma presented with an ovarian mass seven years later.70 Microscopically, the tumor 
consisted of rare foci containing osteoid material and sheets of malignant cells. Three cases of 
Ewing’s sarcoma have also been described with a predominantly diffuse growth of small cells.71-73 
Sporadically, discrete nodules of tumor separated by uninvolved ovary were present. Regarding 
chondrosarcoma, the ovarian tumor of an 18-year old woman showed multiple confluent nodules 
containing small groups and cords of cells as well as single cells in a background that focally 
showed cartilaginous differentiation.72 With respect to rhabdomyosarcoma, Young reported the 
presence of large nodules of neoplastic cells situated primarily in the superficial ovarian cortex as 
well as in several vascular spaces.74
Table 1. The prevalence of ovarian metastasis according to cancer type in women < 50 years of age
Primary tumor Prevalence of ovarian metastasis References
Breast cancer 13.2 - 46.7% 23, 24
Cervical cancer 0.0 - 14.3% 23, 45
Endometrial cancer 1.9 - 41.7% 23, 56-58
Colorectal cancer 2.5 - 33.3% 23
Leukemia <0.7 - 62.3% 23
Lymphoma 10.5 - 13.3% 23
Bone and soft tissue tumors Not reported* Not applicable
* A prevalence rate cannot be provided, since only single cases are reported.
Based on these findings, we conclude that metastases can be confined to a specific region in the 
ovarian cortex. Since the volume of a single cortical ovarian strip is extremely small compared to 
the volume of the entire ovarian cortex,75 examining only one or two cortical ovarian fragments 
that are ultimately not transplanted carries a risk of reintroducing cancer in the patient. It should 
be noted, however, that the vast majority of published data regarding the histological features of 
ovarian metastases are derived from patients with advanced stage disease, whereas most patients 
undergo cryopreservation of ovarian tissue in an early stage of disease. Nevertheless, the paucity 
of available information does not necessarily mean that tumor cells do not reach the ovary in 
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Non-invasive tumor detection methods
One approach to safeguard the transfer of cortical ovarian tissue to the patient would be to 
develop methods that can be used to exclude the presence of metastases in ovarian autografts 
without affecting the tissue’s viability. Two novel techniques might potentially be suitable: near-
infrared fluorescence imaging and full-field optical coherence tomography. 
Near-infrared fluorescence imaging
Near-infrared fluorescence (NIRF) imaging can be used to differentiate malignant tissue from 
healthy tissue in real time without affecting the tissue being examined. The advantages of using 
NIRF imaging rather than visible light include substantial deeper tissue penetration and less 
autofluorescence, thereby rendering sufficient contrast. Because the human eye is insensitive to 
near-infrared light, an imaging system is required to perceive the fluorescent light.76 The imaging 
system is equipped with a spectrally resolved light source that excites a fluorophore and a charge-
coupled device (CCD) camera to image the light emitted from the fluorophore.77,78
In the field of surgical oncology, NIRF imaging has been used successfully using the non-
targeting agents indocyanine green and methylene blue to identify tissues that need to be 
resected, for instance tumors and affected lymph nodes, as well as structures that need to be 
spared, like ureters and bile ducts.79-84 Due to extensive angiogenesis and decreased lymphatic 
drainage, known as the ‘enhanced permeability and retention (EPR) effect’ commonly seen in 
malignancies, these non-specific targeting NIRF agents freely pass through the capillary walls 
and accumulate in the surrounding tumor tissue, thereby revealing the location of cancer.85 
NIRF-labeled tumor-targeting moieties can be used to detect cancer with far more accuracy. 
These tumor-targeting probes consist primarily of two components: firstly, antibodies or peptides 
binding with high affinity to proteins at the cell surface of specific tumor cells, and secondly, a 
fluorophore that emits light in the near-infrared range (λ = 700-900 nm).86,87 The moieties used to 
visualize these tumors exploit the hallmarks of cancer, including increased levels of growth factor 
receptors, limitless replicative potential, sustained angiogenesis, and increased proteolytic activity 
leading to tissue invasion and metastasis.86 
Van Dam et al. were the first to show in-human use of a fluorescent agent beyond the NIR 
spectrum targeted to folate receptor alpha (folate-FITC) to increase the accuracy of cytoreductive 
surgery in patients with primary ovarian cancer.88 The authors showed that ovarian metastases 
could be clearly identified using fluorescence imaging. Our group recently confirmed these results 
in a larger cohort of ovarian cancer patients,89 and demonstrated that the intraoperative use 
of OTL38, a folate analogue conjugated to a NIRF dye, led to an additional 29% resection of 
disseminated ovarian cancer lesions that were otherwise not detected by standard visual and 
tactile inspection.90 Figure 2 shows a peritoneal metastasis from a serous ovarian adenocarcinoma 
that was intraoperatively detected by OTL38. Burggraaf et al. demonstrated that a higher number 
of colorectal polyps could be endoscopically resected after intravenous administration of a 
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also well tolerated by the patients. Two recently published phase I trials reported the feasibility 
of bevacuzimab-IRDye800CW targeting vascular endothelial growth factor (VEGF)-A in breast 
cancer and the therapeutic monoclonal antibody cetuximab targeting epidermal growth factor 
receptor (EGFR) in patients with head and neck cancer, respectively.92,93 Lastly, the activatable 
fluorescent probe LUM015 could be safely administered to breast cancer patients and provided 
excellent tumor-to-normal tissue contrast after cleaving by proteases, which were overexpressed 
by the primary breast tumor.94 The above-mentioned in-human studies emphasize the great 
potential of NIRF imaging in the field of oncology, including the detection of occult metastastic 
disease.
Figure 2. Histopathologic evaluation and fluorescence signal in ovarian cancer 
Representative image of membranous and cytoplasmic accumulation of OTL38 in tumor cells visualized 
by fluorescence microscopy (a). The fluorescence signal is indicated in green, and the nuclei were 
counterstained with DAPI (blue). The fluorescence pattern is consistent with FRα expression analyzed 
with immunohistochemistry (b), and corresponds to a peritoneal metastasis derived from a serous ovarian 
adenocarcinoma, as observed on hematoxylin and eosin (H&E) staining (c). 
In order to use NIRF imaging for the detection of metastatic tumor cells in cortical ovarian tissue 
prior to cryopreservation, a tumor-specific NIRF probe should be intravenously administered to the 
patient before oophorectomy. After oophorectomy, the ovary can be dissected into cortical ovarian 
strips. Because these strips usually measure 5-10 mm in diameter and 1-2 mm in thickness,11 an 
imaging system is required that allows detailed images to be obtained at a depth of at least 1 
mm. A multiphoton microscope seems to be an appropriate device to achieve this.95-97
Full-field optical coherence tomography 
Full-field optical coherence tomography (FF-OCT) generates real-time histology-like images from 
tissue samples at a depth of up to 500 μm.98 The system consists of an upright microscope and 
a reference arm in the Linnik interferometric configuration. The tissue sample is placed under 
the objective and the light reflected or backscattered by the tissue sample interferes with the 
light reflected by the reference mirror. The returning light is then combined and collected by 
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1
performed without the need of tissue manipulation or staining. Studies in breast and skin tissues 
revealed that several distinct tissue types can be distinguished based on their light-scattering 
properties.101,102 For example, adipocytes scatter light poorly and therefore appear as dark 
rounded structures. In contrast, connective tissue scatters light more broadly and appears gray. 
Loose connective tissue has a ‘wavy’ appearance, whereas dense connective tissue appears more 
compact and organized. Figure 3 shows a representative FF-OCT image of primary invasive ductal 
breast cancer in which the collagen bundles can be clearly recognized. Until now, FF-OCT imaging 
has proven its efficacy in detecting lung,100 kidney,103 brain,104 and prostate105 cancer.
Figure 3. Representative FF-OCT image and corresponding histology image of primary invasive 
ductal breast cancer 
Collagen bundles are clearly shown in the FF-OCT image (a), corresponding to the stromal reaction in the 
haematoxylin-and-eosin staining (b). Scale bars represent 500 μm.
This thesis
With the studies presented in this thesis, we aimed to make a step forward in determining 
the safety of ovarian tissue autotransplantation. Besides, we aimed to develop novel detection 
methods by which the actual ovarian autografts can be examined. This thesis therefore focuses 
on further unravelling the accuracy of the current tumor detection approach to establish the need 
for an alternative detection method by which every ovarian autograft can be examined, and the 
feasibility of detecting ovarian metastases by NIRF imaging and FF-OCT. Since breast cancer is one 
of the primary indications for cryopreservation of ovarian tissue and relatively much ovarian tissue 
is available from breast cancer patients due to prophylactic or therapeutic oophorectomies, this 
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Objectives of the work described in this thesis
•	 To establish the prevalence of ovarian metastases among young patients diagnosed 
with primary invasive breast cancer in the Netherlands (chapter 2)
•	 To investigate the clinicopathological characteristics of young women diagnosed with 
primary invasive breast cancer and ovarian metastases, and to identify risk factors for 
the development of ovarian metastases (chapter 2)
•	 To assess the distribution of breast tumor cells in ovarian tissues from young patients 
who were diagnosed with ovarian metastases derived from primary invasive breast 
cancer in order to evaluate the current approach for tumor detection in ovarian tissues 
considered for autotransplantation (chapter 4)
•	 To determine which cell-surface proteins are suitable as a target for tumor-specific 
imaging of ovarian metastases derived from primary invasive breast cancer (chapter 3 
and chapter 4)
•	 To analyze whether invasive breast cancer tissues can be used to predict the most 
suitable target for the detection of ovarian metastases in a particular patient by tumor-
specific imaging (chapter 4)
•	 To examine whether FF-OCT is an appropriate approach for the non-invasive detection 
of ovarian metastases (chapter 5)
In chapter 6, the general discussion, the findings of the work presented in this thesis are 
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Abstract
Background
Breast cancer is one of the primary indications for cryopreservation and subsequent 
autotransplantation of ovarian tissue. The safety of this fertility preservation method remains 
questionable, as the presence of disseminated breast tumor cells cannot yet be excluded in the 
ovarian autografts. We explored the prevalence of ovarian metastases among young breast 
cancer patients and determined risk factors for the development of ovarian metastases.
Methods 
Using the nationwide database of the Dutch Pathology Registry (PALGA), we identified a cohort 
of 2648 women with primary invasive breast cancer at age < 41 years in the period 2000-2010 
in the Netherlands who subsequently underwent an oophorectomy. From this source population, 
all cases who had histologically confirmed ovarian metastases were included. For each case of 
whom clinical data were available, one control without ovarian metastases who matched the time 
interval between breast cancer diagnosis and oophorectomy was selected. Data were collected 
on patient characteristics, diagnosis, treatment and follow-up. 
Results 
Ovarian metastases were found in 63 out of 2648 patients who met the inclusion criteria. The 
risk of developing ovarian metastases increased with time passed since breast cancer diagnosis. 
Multivariate logistic regression analyses showed significant association between tumor stage and 
the development of ovarian metastases (p = 0.024).
Conclusion 
The prevalence of ovarian metastases was 2.4% among young breast cancer patients. Early ovary 
removal may reduce the risk of developing ovarian metastases. In breast cancer patients with 
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Introduction
Breast cancer is the most frequently diagnosed malignancy among women with worldwide 
around 230.000 new cases in 2015.1 Approximately 5% of these women were aged younger 
than 40 years at the time of diagnosis.2 In these young women, chemotherapy may result in 
premature ovarian failure3 and could pose a threat to ovarian function and future childbearing 
potential. Fertility preservation is therefore of crucial importance. In addition to cryopreservation 
of embryos and oocytes, which are currently the most established options to preserve fertility, 
cryopreservation followed by autotransplantation of ovarian tissue is progressively emerging. This 
approach does not only offer young women the chance to conceive and have their own genetic 
offspring, but also provides the opportunity to restore their endocrine function.4,5 In recent series, 
restoration of ovarian activity has been observed in 93% of cases6 and 60 live births have now 
been reported.7
Despite these favorable outcomes, the safety of this method remains of great concern, since 
ovarian tissue may contain malignant cells derived from the primary invasive breast tumor. Previous 
studies, mainly comprising autopsies, prophylactic and therapeutic oophorectomies, showed that 
ovarian metastases occur in 13-47% of breast cancer patients.8-10 By contrast, in early-stage breast 
cancer patients who were eligible for cryopreservation of ovarian tissue, immunohistochemical 
examination of cortical ovarian biopsies did not disclose any malignant cells.11-13 Quantitative PCR 
analysis of frozen-thawed cortical ovarian fragments from patients with advanced-stage breast 
cancer revealed cells that expressed the mammaglobin B (MGB2) gene, which is associated with 
breast cancer.14 However, whether these cells bear any malignant potential remains unclear. 
Although the results with respect to cryopreservation of ovarian tissue are relatively 
reassuring, it should be stressed that only a few cortical ovarian fragments were included for 
analysis, since the current tumor detection methods (i.e. immunohistochemistry, PCR analysis) 
render the ovarian tissues unsuitable for autotransplantation. It therefore remains difficult to 
estimate the prevalence of ovarian metastases in breast cancer patients who are considered for 
ovarian tissue cryopreservation. Furthermore, as a consequence of this approach, malignant cells 
that have disseminated to the ovarian autografts cannot be excluded and might be reimplanted 
upon autotransplantation of ovarian tissue. 
In this study, we aimed to explore the prevalence of ovarian metastases among young patients 
diagnosed with primary invasive breast cancer in order to assess the risk of reimplanting malignant 
cells following autotransplantation of ovarian tissue. In addition, we identified risk factors 
associated with the presence of ovarian metastases in young patients diagnosed with primary 
invasive breast cancer in order to more thoroughly define selection criteria for cryopreservation of 
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Methods
Patient selection and data collection of the study population
Via a nationwide search performed by PALGA, the Dutch histopathology and cytopathology 
network and archive that encompasses all pathology laboratories within the Netherlands,15 a 
source population was compiled. This source population consisted of all patients who were 
diagnosed with primary invasive breast cancer at age < 41 years in the period 2000-2010 who 
subsequently underwent a unilateral or bilateral oophorectomy for any reason (n = 2648; Figure 
1). From this source population, all patients who had histologically confirmed ovarian metastases 
derived from primary invasive breast cancer were selected (n = 69; cases). Patients who were 
diagnosed with primary ovarian cancer or a borderline ovarian malignancy were excluded (n = 44). 
From the remaining group of patients who had normal ovaries or benign ovarian abnormalities 
(n = 2535; controls), all patients who were treated in the same hospitals as the cases were taken 
(n = 2036). For each case of whom clinical data were available (n = 57), one control without 
ovarian metastases was included who matched the time interval between the diagnosis of breast 
cancer and oophorectomy (n = 57; matched controls). 
Clinical data were extracted from the patient’s files after approval by the medical ethical 
committee of the Leiden University Medical Center (protocol number P14.106) and the local 
ethical committee of the participating hospitals. Data were collected on patient characteristics, 
diagnosis of breast cancer, treatment and follow-up. Furthermore, data were sought on date of 
oophorectomy, age at oophorectomy, reasons to perform ovarian surgery and diagnosis. 
From the primary invasive breast tumors in which the HER2/neu gene amplification status 
was not yet determined, formalin-fixed paraffin-embedded (FFPE) tissue samples were requested 
from the pathology laboratories. Following this, immunohistochemistry was performed on 3-μm 
thick FFPE tissue sections using primary antibodies against Her2/neu (ERBB2, rabbit polyclonal, 
Dako, Denmark), as described previously.16 Primary invasive breast tumors that showed 
immunohistochemical reactions of 0 and 1+ were considered negative. In primary invasive 
breast tumors that showed 2+ or 3+ immunohistochemical reaction,17 chromogenic silver in situ 
hybridization (SISH) was carried out using the Ventana SISH kit on Benchmark XT to establish the 
final HER2/neu status (amplification or no amplification).18 
All patient samples and clinical data were handled in accordance with the medical ethics 
guidelines described in the Code of Conduct for Proper Secondary Use of Human Tissue of the 
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Figure 1. Flow chart of selection of cases and matched controls
The source population was compiled by the Dutch histopathology and cytopathology network. The exclusion 
criteria are indicated in the dotted boxes. 
 
Validation of the control population
In order to estimate whether the matched controls to some extent also reflected women 
diagnosed with primary invasive breast cancer at age < 41 years whose ovaries remained in 
situ, the matched controls were compared to a cohort of patients who did not undergo an 
oophorectomy. To this end, all patients diagnosed with primary invasive breast cancer at age < 41 
years who were treated in the corresponding 54 hospitals, were selected from the Dutch Cancer 
Registry (n = 7299; Figure 2). After notification by PALGA, patients who had undergone an 
oophorectomy or who were either not or double registered in the PALGA registry, were excluded 
(n = 2355). The remaining group of patients exclusively consisted of breast cancer patients who 
were younger than 41 years of age at the time of diagnosis and did not undergo ovarian surgery 
(n = 4944). From these patients, data on the diagnosis of breast cancer, staging and treatment 
were collected from the medical records by trained registry personnel using the registration and 
coding manual of the Comprehensive Cancer Center the Netherlands (CCCN). This group of 
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Figure 2. Flow chart of selection of patients diagnosed with primary invasive breast cancer at age 
< 41 years who did not undergo an oophorectomy
This cohort of patients was compiled by the Comprehensive Cancer Center the Netherlands (CCCN) and 
indicated as CCCN controls in the study. The exclusion criteria are indicated in the dotted box.
Statistical analysis   
Statistical analysis was performed using SPSS version 23.0 (IBM, Armonk, NY). Logistic regression 
analyses were used to identify predictors for the development of ovarian metastases in the study 
population and for comparing the current control group with the cohort of CCCN controls. Missing 
values were accounted for by 10-fold multiple imputation, in which all risk factors and the case-
control status in the imputation models were included. In some cases, logistic regression analyses 
could not be performed because of empty categories. In those cases, the Pearson Chi-square test 
was used. Factors that were associated with the development of ovarian metastases (p < 0.100) 
in univariate logistic regression models were included in multivariate logistic regression analyses. 
Survival rates were calculated according to the Kaplan Meier method. Statistical significance was 
assigned at the level of p < 0.05. 
Results
Prevalence of ovarian metastases
According to the PALGA registry, 2648 patients were diagnosed with primary invasive breast 
cancer at age < 41 years in the period 2000-2010 who subsequently underwent a unilateral or 
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confirmed ovarian metastases. Yet, in one patient the registry data did not correspond to the 
final pathological diagnosis. Moreover, in five patients the diagnosis of primary invasive breast 
cancer was made before the study period. Thus, strictly, ovarian metastases were found with a 
prevalence of 2.4% (63 out of 2642) in patients with primary invasive breast cancer at age < 41 
years in the period 2000-2010 in the Netherlands.
Clinicopathological characteristics of the cases
Clinical data were available for 57 patients diagnosed with primary invasive breast cancer and 
ovarian metastases (Figure 1). The median age at the time of breast cancer diagnosis was 37.0 
years (range 28-40 years). Ten patients (17.5%) were tested for the presence of a BRCA gene 
mutation and one of them resulted positive; the BRCA gene mutation status in the remaining 
patients was unknown. Forty-four patients (77.2%) were diagnosed with invasive ductal 
breast cancer and eight patients (14.0%) were diagnosed with invasive lobular breast cancer. 
The remaining five patients (8.8%) had invasive ductolobular breast cancer. Fifty-one patients 
(89.5%) had hormone-sensitive breast cancer. HER-2/neu gene amplification was observed in 
eight of 56 tumor samples tested (14.3%); of the remaining tumor, no tissue was available. The 
majority of patients had positive axillary lymph nodes and 41 patients (71.9%) had tumors larger 
than 2 cm in diameter of whom five patients presented with inflammatory breast cancer. Nine 
patients (15.8%) had distant metastases outside the ovary at the time of diagnosis of primary 
invasive breast cancer; eight patients had bone metastases of whom two had synchronous liver 
metastases, and one patient was diagnosed with both pulmonary and retinal metastases. Surgical 
resection of the primary breast tumor was performed by either breast conserving surgery (18 
patients; 31.6%) or mastectomy (33 patients; 57.9%). Six patients (10.5%) did not undergo 
any surgical treatment, because of diffuse metastatic disease. Adjuvant chemotherapy was 
administered to 35 patients (61.4%), 36 patients (63.2%) underwent locoregional radiotherapy 
and 45 patients (78.9%) received hormonal treatment. 
The median time between the diagnosis of breast cancer and oophorectomy was 48.7 months 
(range 0.3-141.8 months). Apart from the nine patients who already had distant metastases at 
the onset of breast cancer, 33 patients (57.9%) developed a locoregional or distant recurrence 
prior to oophorectomy. The presence of ovarian metastases was the first manifestation of 
recurrent disease in fifteen patients (26.3%). Thirty-four patients (59.6%) had ovarian metastases 
in both ovaries. In seven patients (12.3%) one or both fallopian tubes were involved, whereas 
in 33 patients (57.9%) the fallopian tubes were free of metastatic disease. Of the remaining 17 
patients (29.8%), no data on the fallopian tubes were available. Seven patients (12.3%) had 
peritonitis carcinomatosa at the time of oophorectomy. The median duration of follow-up was 
152.8 months (range 9.9-166.6 months). During follow-up, 43 patients (75.4%) died, all because 
of metastatic breast cancer. The median time from the diagnosis of ovarian metastases to death 
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Risk factor analysis for the development of ovarian metastases
The time interval between the diagnosis of breast cancer and oophorectomy significantly differed 
between the 63 cases who were diagnosed with ovarian metastases and who met the inclusion 
criteria, and the 2535 controls without ovarian metastases in the source population, 47.0 and 
32.0 months, respectively (p = 0.002). In order to identify baseline risk factors that are associated 
with the development of ovarian metastases, the time interval between the diagnosis of breast 
cancer and oophorectomy should be comparable between the cases and controls. Therefore, the 
57 cases of whom clinical data were available, were matched on this time interval to an equally 
large cohort of controls (Figure 1). 
Table 1 shows the indications for oophorectomy in the cases and the matched controls. The 
cases had significantly more often abnormal ovaries on preoperative transvaginal ultrasonography 
or MRI than the matched controls, 26.3% versus 3.5%, respectively (p = 0.000). The two matched 
controls who presented with abnormal ovaries were diagnosed with a serous cystadenoma and 
an epithelioid cell granuloma, respectively. The 42 cases who presented with normal ovaries 
on transvaginal ultrasound underwent oophorectomy because of prophylactic or therapeutic 
reasons. In those cases, the ovarian metastases were clinically indolent. This emphasizes the need 
to determine which young breast cancer patient is at risk of developing ovarian metastases.
Table 1. Indications for oophorectomy in patients diagnosed with primary invasive breast cancer at 
age < 41 years with and without ovarian metastases 
Cases Matched controls p-value
  N = 57 % N = 57 %
Indication for oophorectomy 0.000
Prophylactic because of breast cancer 11 19.3 39 68.4
Therapeutic because of breast cancer 31 54.4 15 26.3 
Abnormal ovaries on ultrasound 15 26.3 2 3.5
Unknown 0 0.0 1 1.8
The cases with ovarian metastases were matched on the time interval between the diagnosis of breast 
cancer and oophorectomy to an equally large cohort of controls without ovarian metastases, as shown in the 
flow chart of Figure 1. The Pearson Chi-square test was used to compare the indications for oophorectomy 
between the cases and matched controls. P-values < 0.05 were considered statistically significant.
Table 2 shows the results of the univariate and multivariate logistic regression analyses that 
were performed in the matched case-control population. Univariate logistic regression analyses 
revealed that the risk of developing ovarian metastases significantly increased with tumor size 
and the presence of inflammatory breast cancer, the number of positive lymph nodes and the 
presence of distant metastases. In the multivariate logistic regression analyses, only a larger tumor 
size (i.e. > 5 cm) and the presence of inflammatory breast cancer was significantly associated with 
the development of ovarian metastases (p = 0.024). The presence of distant metastases could not 
be included in the multivariate logistic regression analyses, as none of the matched controls had 
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Table 2. Clinicopathological characteristics of patients diagnosed with primary invasive breast 
cancer at age < 41 years with and without ovarian metastases




  N = 57 % N = 57 % p-value p-value
Age at diagnosis of breast cancer, 
years - median (range)
37 (28 - 40) 36 (27 - 40) 0.730 n.a.





















































































































































* Values are statistically significant; n.a. = not applicable.
The cases with ovarian metastases were matched on the time interval between the diagnosis of breast cancer 
and oophorectomy to an equally large cohort of controls without ovarian metastases, as shown in the flow 
chart of Fig 1. Univariate and multivariate logistic regression analyses were used to compare the cases and 
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Table 3. Clinicopathological characteristics of patients diagnosed with primary invasive breast 
cancer at age < 41 years with and without oophorectomy
Characteristics Matched controls CCCN controls p-value
  N = 57 % N = 4944 %
Age at diagnosis of breast cancer, years - median (range) 36 (27 - 40) 37 (18 - 40) 0.347














































































































































































* Values are statistically significant.
Patients without ovarian metastases were indicated as matched controls, of whom selection is shown in the 
flow chart of Figure 1. Patients without oophorectomy were indicated as CCCN controls, of whom selection 
is illustrated in the flow chart of Figure 2. Univariate logistic regression analyses were used to compare the 
matched controls and CCCN controls for the clinicopathological characteristics as indicated in the table. 
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Validation of the control population
Table 3 shows that, apart from the fact that more hormone-sensitive breast tumors were 
diagnosed in the matched controls than in the CCCN controls, 75.4% compared to 31.2%, 
respectively (p = 0.047), no statistically significant differences were found. These data indicate 
that the clinicopathological characteristics of the matched controls broadly corresponded to 
those of women whose ovaries remained in situ. 
 
Discussion
In the current Dutch nationwide retrospective cohort study, we found that ovarian metastases 
occurred in 2.4% of young women diagnosed with primary invasive breast cancer who 
subsequently underwent an oophorectomy. This percentage is much lower than the previously 
reported prevalence rates of 13-47%.8-10 The discrepancy between our findings and those reported 
in the literature can be explained by the fact that the prevalence rates were explored in different 
patient populations. In previous studies, the prevalence rates were primarily derived from clinical 
studies in patients with disseminated breast cancer who underwent therapeutic oophorectomy, 
and autopsy reports of patients who died of metastastic breast cancer.8-10 Our findings were based 
on a nationwide cohort mainly consisting of young breast cancer patients in whom the ovaries 
were either removed prophylactically because of a positive family history and/or the presence of 
a BRCA gene mutation, or therapeutically because of hormone-sensitive breast cancer. Hence, 
our findings provide more insight into the prevalence of ovarian metastases in the general 
population of young breast cancer patients. Nonetheless, some remarks on the establishment 
of this prevalence rate should be made. Firstly, the prevalence of ovarian metastases was solely 
substantiated among young breast cancer patients who underwent an oophorectomy. The 
reason for this was that ovarian metastases can only be diagnosed with certainty by microscopic 
examination.21 The prevalence of ovarian metastases among young breast cancer patients whose 
ovaries remained in situ thus remains elusive. This point might also be considered as a strength of 
the current study, as our findings are exclusively based on a large cohort of young breast cancer 
patients in whom the presence of ovarian metastases could be determined. Secondly, it should be 
noted that the majority of the ovarian tissues were not completely examined, since sequentially 
cut tissue sections were often not obtained using standard pathology procedures. As a result, 
malignant cells might have been overlooked, thereby potentially resulting in an underestimation 
of the prevalence of ovarian metastases among young breast cancer patients. Thirdly, the time 
between breast cancer and the onset of ovarian metastases was on average 42 months, whereas 
in patients who undergo ovarian tissue cryopreservation an oophorectomy is usually performed 
soon after initial diagnosis. Fourthly, the majority of the patients included in this study were 
treated with chemotherapy, which may have treated distant metastases if present. Lastly, 26% of 
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Each of these factors might have affected the prevalence rate to some extent. Nonetheless, 
the prevalence rate based on the current study represents the closest possibility to come to a 
prevalence of ovarian metastases among young breast cancer patients who may undergo ovarian 
tissue autotransplantation, since frozen-thawed cortical ovarian fragments from patients who are 
willing to undergo ovarian tissue autotransplantation cannot be used to estimate the prevalence 
rate. Examination of cortical ovarian tissue fragments from deceased patients will certainly yield 
too small study populations to draw reliable conclusions from.
The most striking difference between the cases and controls in the source population was 
the difference in time interval between the diagnosis of breast cancer and oophorectomy. Due to 
the retrospective study design, it was impossible to find out why the ovaries were much earlier 
removed in the controls than in the cases. Nevertheless, these findings suggest that the risk of 
developing ovarian metastases increases with the passage of time. Hence, in young breast cancer 
patients who wish to preserve their fertility, it seems important to perform an oophorectomy 
soon after the diagnosis of breast cancer in order to reduce the risk for the development of 
ovarian metastases. Besides, some recommendations can be proposed with respect to the site 
of ovarian tissue autotransplantation. As long as there is no accurate alternative to the current 
tumor detection approach available by which the actual ovarian autografts can be examined, 
it would be advisable to transplant the cortical ovarian fragments back to the remaining ovary 
rather than, for instance, a peritoneal window. After all, transplantation of the cortical ovarian 
fragments to the remaining ovary enables the complete removal of the grafted ovarian tissues 
at a later stage by simply extirpating the entire ovary, for instance when the patient’s family 
has been completed or when the ovarian grafts have ceased functioning. By contrast, in case 
the cortical ovarian fragments are transplanted to a peritoneal window, complete extraction of 
these fragments cannot be guaranteed, as it will be difficult to retrace the ovarian autografts 
within the peritoneum. Thus, transplantation to the remaining ovary should be preferred over 
transplantation to the peritoneum as it may further minimize the risk that tumor cells in the 
ovarian grafts ultimately develop into ovarian metastases. Lastly, in the patients who were 
diagnosed with ovarian metastases, it is plausible that tumor cells have disseminated very early 
after the onset of cancer and have long remained dormant before they formed overt metastases 
in the ovaries.22,23 Our findings therefore do not alter the fact that minimal residual disease should 
be excluded in the actual ovarian autografts in order to avoid a cancer relapse following ovarian 
tissue autotransplantation. 
Because the presence of ovarian metastases is inextricably linked to the time of oophorectomy, 
baseline risk factors could only be determined if the time interval between the cases and controls 
was comparable. The most suitable approach to achieve this would be to subject every young 
patient who is diagnosed with primary invasive breast cancer to a bilateral oophorectomy after 
a certain predefined time interval and subsequently evaluate whether ovarian metastases have 
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therefore circumvented this by matching the 57 cases, of whom clinical data were available, 
to an equally large cohort of controls on this time interval, making accurate risk factor analyses 
possible. These risk factor analyses showed that a larger tumor size (i.e. > 5 cm) and the presence 
of inflammatory breast cancer resulted in an increased risk of developing ovarian metastases. Yet, 
because the matched controls did not fully reflect the general population of young breast cancer 
patients without ovarian metastases, the magnitude of association between the tumor stage and 
the risk of developing ovarian metastases has limited value for clinical practice. 
Although other reports stated that lobular breast cancers are more likely to metastasize to the 
ovary than ductal breast cancers,21 we did not observe any significant differences in histological 
subtype between the cases and matched controls. This might be different in elderly women with 
breast cancer, as lobular breast cancers are more frequently diagnosed in older patients.24  
Information on BRCA gene mutation status was available from 10 cases (17.5%) and 21 
matched controls (36.8%). Compiled data from 18 studies reporting a total of 1187 women 
with BRCA mutations who underwent risk-reducing salpingo-oophorectomy revealed only two 
patients (0.17%) with metastatic breast cancer in the ovaries.25 Hence, the presence of a BRCA 
gene mutation does not seem to be associated with the risk of developing ovarian metastases in 
patients with breast cancer and was therefore not taken into account in our risk factor analyses. 
Nevertheless, risk-reducing salpingo-oophorectomy is often recommended to BRCA gene 
mutation carriers to reduce their risk of developing primary ovarian cancer.26 
As described above, patients were only enrolled in the current study if they had undergone 
ovarian surgery. Nevertheless, a comparison of our matched controls to young breast cancer 
patients whose ovaries remained in situ (CCCN controls) showed that the clinicopathological 
characteristics were broadly similar between the two groups. The reason that our matched 
controls were more often diagnosed with hormone-sensitive breast tumors relies on the fact that 
the indication for oophorectomy in these patients was primarily therapeutic. Hence, apart from 
the difference in hormone receptor expression, the intrinsic tumor characteristics of our matched 
controls were passably in line with those of young breast cancer patients whose ovaries remained 
in situ. 
In conclusion, our research shows that secondary ovarian involvement is encountered in 2.4% 
of young breast cancer patients. In order to minimize the risk of developing ovarian metastases 
in young breast cancer patients who wish to preserve their fertility, we recommend early ovary 
removal followed by transplantation of cortical ovarian tissue fragments to the remaining ovary. 
Ultimately, when the patient’s family has been completed or when the ovarian grafts have ceased 
functioning, the remaining ovary to which the cortical ovarian tissue fragments were transplanted 
should preferably be removed in order to keep the risk of developing ovarian metastases as low 
as possible. In addition, we suggest a cautious approach to ovarian tissue autotransplantation in 
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Supplementary figure S1. Data of patients diagnosed with primary invasive breast cancer at age 
< 41 years with and without ovarian metastases. The cases with ovarian metastases were matched on 
the time interval between the diagnosis of breast cancer and oophorectomy to an equally large cohort of 
controls without ovarian metastases, as shown in the flow chart of Figure 1. N.A. = Not applicable; NED = No 
evidence of disease; AWD = Alive with disease; DOC = Dead of other cause; DOD = Dead of disease; DSS = 
Disease-specific survival. 
See online: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0168277
Supplementary figure S2. Data of patients diagnosed with primary invasive breast cancer at 
age < 41 years who did not undergo an oophorectomy. This cohort of patients was compiled by the 
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Abstract
Background
The safety of ovarian tissue autotransplantation in oncology patients cannot be ensured, 
as current tumor-detection methods compromise the ovarian tissue viability. Although non-
destructive methods (for instance near-infrared fluorescence imaging) can discriminate malignant 
from healthy tissues while leaving the examined tissues unaffected, they require specific cell-
surface tumor markers. We determined which tumor markers are suitable targets for tumor-
specific imaging to exclude the presence of breast cancer cells in ovarian tissue.
Methods 
Immunohistochemistry was performed on formalin-fixed paraffin-embedded specimens of ten 
ovaries from premenopausal patients. Additionally, we screened a tissue microarray containing 
tumor tissue cores from 24 breast cancer patients being eligible for ovarian tissue cryopreservation. 
The following cell-surface tumor markers were tested: E-cadherin, EMA (epithelial membrane 
antigen), Her2/neu (human epidermal growth factor receptor type 2), αvβ6 integrin, EpCAM 
(epithelial cell adhesion molecule), CEA (carcinoembryonic antigen), FR-α (folate receptor-alpha), 
and uPAR (urokinase-type plasminogen activator receptor). For each tumor, the percentage of 
positive breast tumor cells was measured.
Results 
None of the ten ovaries were positive for any of the markers tested. However, all markers (except 
CEA and uPAR) were present on epithelial cells of inclusion cysts. E-cadherin was present in the 
majority of breast tumors: ≥90% of tumor cells were positive for E-cadherin in 17 out of 24 
tumors, and 100% of tumor cells were positive in 5 out of 24 tumors.
Conclusion 
Of the markers tested, E-cadherin is the most suitable marker for a tumor-specific probe in ovarian 
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Introduction
Premature ovarian failure is the most common long-term major adverse effect in premenopausal 
women following chemotherapy.1 Because loss of fertility can significantly decrease quality of 
life,2 considerable effort has been devoted to offering these patients options for preserving their 
fertility. These options currently include cryopreservation of embryos and/or oocytes. Besides, 
autotransplantation of pretreatment cryopreserved ovarian tissue is becoming more prevalent 
and is considered predominantly feasible for both prepubescent girls and women who cannot 
postpone adjuvant therapy.3-5 
Although autotransplantation of frozen-thawed ovarian tissue has improved greatly in recent 
years,6-7 its safety is questionable for certain types of cancer at risk of ovarian involvement, as 
it remains uncertain whether the transplanted cortical ovarian strips contain metastatic cells. 
This uncertainty arises from the highly damaging effects of currently available tumor-detection 
methods (e.g., PCR, immunohistochemistry) on tissue viability.8-9 Therefore, traditional screening 
is performed using a limited number of ovarian strips that are ultimately not transplanted. As a 
consequence of this approach, autotransplanting ovarian tissue involves the risk of reimplanting 
diseased cells that can lead to cancer relapse in some patients. 
To safeguard the transfer of cortical ovarian tissue to the patient, methods must be 
developed in which tumor cells can be detected in ovarian autografts while preserving the tissue’s 
reproductive function. Near-infrared fluorescence (NIRF) imaging might be a suitable approach, 
as this technique can safely distinguish malignant tissues from non-malignant tissues in real time 
while leaving the tissues viable.10 A NIRF probe consists of a fluorophore that emits light in the 
near-infrared spectrum (λ = 700-900 nm) conjugated to an antibody or peptide with high affinity 
for a protein marker expressed selectively at the cell surface of tumor cells.11-12 
The first step towards developing tumor-specific imaging is the identification of protein 
markers that are present selectively at the cell surface of tumor cells, but absent on cells within the 
normal ovarian cortex. Because breast cancer is one of the primary indications for cryopreservation 
of ovarian tissue13-16 and breast cancer metastases in the ovaries have been reported with a 
prevalence ranging from 13 to 47%,8,17 we examined a panel of cell-surface markers known to 
be expressed by breast cancer cells. This panel included human epidermal growth factor receptor 
type 2 (Her2/neu),18-19 E-cadherin,20 and carcinoembryonic antigen (CEA).21 In addition, we tested 
several markers involved in tumor invasion and migration, including epithelial cell adhesion 
molecule (EpCAM),22-23 αvβ6 integrin,24 urokinase-type plasminogen activator receptor (uPAR),25-
26 and epithelial membrane antigen (EMA, also known as MUC1).27-28 Lastly, we included folate 
receptor alpha (FR-α), which is expressed in several tumor types but not in normal ovarian tissue.29 
We excluded cytokeratin CAM 5.2, gross cystic disease fluid protein-15 (GCDFP15), Wilms’ tumor 
antigen-1 (WT1), mammaglobin 1, and cytokeratin 7 (CK-7), which were used previously by 
Sánchez-Serrano et al.30 and Rosendahl et al.,31 as these proteins are not expressed at the cell 
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In this study, we measured the expression levels of the above-mentioned markers in breast 
cancer cells obtained from patients who were potentially eligible for cryopreservation of ovarian 
tissue. In addition, we compared these expression levels to expression in normal ovarian tissues.
Material and methods
Control ovaries
Formalin-fixed, paraffin-embedded (FFPE) specimens of control ovaries obtained from 
premenopausal patients who underwent a unilateral or bilateral oophorectomy in 2001-2012 
were selected from the archives of the Department of Pathology at the Leiden University 
Medical Center (LUMC). The clinical data were extracted from the patients’ medical records. 
Indications for surgery included suspected malignancy in the contralateral ovary, early-stage 
uterine sarcoma, endometrial carcinoma, squamous cell carcinoma of the cervix, or enlarged 
ovary during pregnancy. BRCA mutation carriers and women with unknown BRCA mutation 
status were excluded. Patients who used a gonadotropin-releasing hormone (GnRH) agonist or 
oral contraceptives prior to oophorectomy were excluded to ensure that only functionally active 
ovaries were studied. A pathologist specialized in gynecology confirmed the absence of overt 
abnormalities in the ovaries by reviewing hematoxylin-and-eosin-stained sections. A total of ten 
control ovaries from ten different patients were included. 
Breast cancer tissue
Breast tumor samples were collected from 24 patients who were potentially eligible for 
cryopreservation of their ovarian tissue based on the inclusion criteria established by the Dutch 
Network of Fertility Preservation.32 All women were ≤35 years of age and were diagnosed with 
invasive breast carcinoma for which they were treated surgically at the LUMC in 1997-2009. The 
following data were obtained from the medical records: age at the time the tissue was obtained, 
TNM (tumor/node/metastasis) stage, histological subtype, Scarff-Bloom-Richardson (SBR) grade, 
and expression of the estrogen and progesterone receptors. All patients were eligible for adjuvant 
chemotherapy based on the current protocols, and none was diagnosed with distant metastases. 
Immunohistochemistry
Immunohistochemistry was performed on 4-μm thick FFPE sections of control ovaries and 
4-μm thick slices of a tissue microarray (TMA) containing invasive breast tumor cores. To 
generate the TMA, tissue biopsies measuring 1.0 mm in diameter were taken in triplicate from 
representative regions of the FFPE tumor samples and arrayed into a new recipient paraffin block 
using TMA Master (3DHistech, Hungary). The tissue sections were deparaffinized in xylene, 
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blocking endogenous peroxidase activity with 0.3% hydrogen peroxide for 20 minutes, heat-
induced antigen retrieval was performed by placing the slides in EnVision Flex Target Retrieval 
Solution high pH/low pH in PT Link (Dako, Denmark). EpCAM and αvβ6 integrin epitopes were 
unmasked by 30-minute incubation with 0.125% trypsin and 0.4% pepsin, respectively, at 
37° C. The sections were incubated overnight in a humidified chamber at room temperature 
with primary antibodies against Her2/neu (ERBB2, rabbit polyclonal, Dako), E-cadherin (NCH38, 
mouse monoclonal, Dako), EpCAM (323/A3, mouse monoclonal, provided by the Department 
of Pathology, LUMC, the Netherlands), CEA (A0115, rabbit polyclonal, Dako), αvβ6 integrin 
(6.2A1, mouse monoclonal, Cell Essentials), uPAR (ATN615, mouse monoclonal, kindly provided 
by Prof. A.P. Mazar, Northwestern University, Evanston, IL), or EMA (E29, mouse monoclonal, 
Dako); all primary antibodies were used at their predetermined optimal dilution. Some sections 
were incubated in an antibody against FR-α (26B3.F2, mouse monoclonal, Biocare Medical) 
for 60 minutes in accordance with the manufacturer’s instructions. After incubation with the 
primary antibody, the sections were rinsed with PBS, incubated with secondary antibody (anti-
mouse or anti-rabbit EnVision; Dako) for 30 minutes, and visualized using liquid DAB+ substrate 
buffer (Dako). The sections were counterstained with Mayer’s hematoxylin solution, dehydrated, 
and permanently mounted with Pertex (Leica Microsystems, Germany). For each immunostain, 
a positive control expressing the antigen of interest was included. The primary antibody was 
omitted as a negative control. 
Image capture and quantification of immunoreactivity
The immunostained slides were scanned using a Pannoramic MIDI digital slide scanner (3DHistech, 
Hungary). Immunohistochemical staining of the ovary sections was evaluated by the primary 
researcher (I.P.) and an experienced pathologist specialized in gynecology (V.S.). In each breast 
tumor tissue core sample, the percentage of breast tumor cells and the percentage of positively 
stained membranes among the malignant cells were scored by two independent observers (I.P. 
and R.V.). In the event of a major discrepancy, the observers reached consensus regarding a final 
score. The tumor cell membranes were considered positive if they showed immunoreactivity of 
any intensity. A weighted scoring method based on the size of the tumor area in each tumor core 
was used to calculate the percentage of positive membrane-stained tumor cells in each sample. 
Statistical analysis
Statistical analysis was performed using SPSS version 20.0 (IBM, Armonk, NY). Inter-observer 
agreement was calculated using the Pearson correlation coefficient. The suitability threshold for 
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Results
Control ovaries
A histological analysis showed that all ovaries contained follicles. The cortex of each ovary was 
negative for immunohistochemical staining by all markers tested. In contrast, all markers (except 
CEA and uPAR) were detected at the plasma membrane of epithelial cells in inclusion cysts (Figures 
1a and 1b). These inclusion cysts were present in five of the ten ovaries. In addition, E-cadherin 
was expressed at moderate levels in the granulosa cells of primary follicles (Figure 2). 
   
Figure 1. Immunohistochemical expression of the investigated markers in ovarian cortices and 
inclusion cysts
a. Immunohistochemical expression of E-cadherin, EMA, Her2/neu and αvβ6 integrin. Stromal cells stained 
negative, but E-cadherin, EMA, Her2/neu and αvβ6 integrin showed expression at the epithelial cells of 
inclusion cysts. 
b. Immunohistochemical expression of EpCAM, CEA, FR-α and uPAR. Stromal cells stained negative, but 
EpCAM and FR-α showed expression at the epithelial cells of inclusion cysts. Scale bar in the upper panel 
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Figure 2. Immunohistochemical expression of E-cadherin in the granulosa cells of primary follicles 
in the ovarian cortex
Moderate expression of E-cadherin in the granulosa cells of primary follicles in the ovarian cortex is indicated 
by arrows. Scale bar represents 200 μm. 
Breast cancer tissue
The median age at the time of diagnosis was 32 years (range 21-35 years) for the 24 patients 
included in the TMA analysis. Twenty-three patients were diagnosed with ductal breast cancer, 
and the remaining patient was diagnosed with lobular breast carcinoma. The characteristics of 
these 24 patients and their tumors are summarized in Table 1.
Table 1. Clinicopathologic characteristics of premenopausal patients with primary invasive breast cancer
Characteristic N = 24
Age at diagnosis, years - median (range) 32.0 (21 - 35) 
Tumor size, mm - median (range) 20.5 (10 - 45) 
Tumor stage - no. (%)
     pT1 11 (45.8)
     pT2 12 (50.0)
     pT3 1 (4.2)
     pT4 0 (0.0)
Lymph node involvement - no. (%)
     pN0 13 (54.2)
     pN1 11 (45.8)
Scarff-Bloom-Richardson grade - no. (%)
     I 2 (8.3)
     II  9 (37.5)
     III 13 (54.2)
Histological subtype - no. (%)
     Ductal 23 (95.8)
     Lobular 1 (4.2)
Estrogen receptor - no. (%)
     Negative 12 (50.0)
     Positive 9 (37.5)
     Unknown 3 (12.5)
Progesterone receptor - no. (%)
     Negative 15 (62.5)
     Positive 6 (25.0)








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Expression of investigated markers
Microscopic quantification of marker levels was possible in all breast tumor samples. Strong 
correlation was obtained between the scoring results obtained by the two observers; the median 
R2 was 0.746 (range 0.626-0.818). E-cadherin, EMA, Her2/neu, CEA, and uPAR staining was 
positive in both the plasma membrane and cytoplasm of the breast cancer cells, whereas αvβ6 
integrin, EpCAM, and FR-α staining was confined to the membrane. In addition, uPAR staining 
was observed in stromal cells surrounding the tumor cells (Figure 3). 
The median (range) percentage of positive tumor cells was 94% (5-100) for E-cadherin, 78% 
(13-100) for EMA, 61% (11-100) for Her2/neu, 56% (2-100) for αvβ6 integrin, 54% (0-100) for 
EpCAM, 23% (0-100) for CEA, and 3% (0-100) for FR-α. uPAR was expressed in extremely few 
tumor and stromal cells, 0% (0-11) and 0% (0-14), respectively (Table 2). 
Figure 3. Immunohistochemical expression of E-cadherin, EMA, Her2/neu, αvβ6 integrin, EpCAM, 
CEA, FR-α and uPAR in invasive breast cancer
uPAR was barely expressed in stromal cells surrounding the tumor (arrows). Scale bars represent 100 μm. 
Potential targets for imaging
Given that breast cancer is relatively heterogeneous and that the expression of antigens varied 
among the tumors examined (Table 2), targeting one membrane protein would likely be insufficient 
for detecting all possible tumor cells in each patient. Therefore, to facilitate the selection of 
possible targets, we used suitability thresholds set at 80, 90, and 100%, corresponding to the 
percentage of tumor cells that expressed the various antigens.  
Figure 4 summarizes the suitability of each tumor marker for detecting invasive tumor cells in 
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identified as the most suitable marker for detecting breast cancer cells; specifically, E-cadherin 
was present in 100% of cells in five tumors, and this marker was present in ≥90% of cells in 17 
tumors. The seven tumors with <90% positivity for E-cadherin were positive for the markers EMA 
(1 tumor; 100% of cells detected), αvβ6 integrin (3 tumors; 78-93% of cells detected), EpCAM 
(1 tumor; 81% of cells detected), E-cadherin (1 tumor; 80% of cells detected), and Her2neu (1 
tumor; 76% of cells detected). Two tumors had <80% positivity for all of the markers tested 
(Table 2). In these two tumors, 76% and 78% of the tumor cells were detected by the markers, 
corresponding to a maximum of 24% and 22% of undetected malignant cells, respectively.
Figure 4. Suitability of tumor markers to use as a target for the detection of tumor cells in 24 
premenopausal women with invasive breast cancer
Columns represent the number of tumors in which at least 80%, at least 90% or 100% of the tumor cells 
showed expression of the tumor markers. For uPAR, stromal cell expression is also shown. 
Discussion
Here, we identified several proteins that could potentially serve as a suitable target for detecting 
breast cancer cells within ovarian autografts. One clear application for these markers is the use 
of NIRF imaging, a technique that can differentiate malignant tissues from non-malignant tissues 
without reducing the tissue’s viability.10,33-35 Designing a NIRF probe directed against E-cadherin 
shows particular promise, as E-cadherin was expressed by the majority (94%) of invasive breast 
tumor cells and was absent on the surface of normal ovarian cells. However, a combination of 
tumor-selective probes will likely be needed to detect all tumor cells. Based on our results, a 
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Metastatic spread requires the local invasion of the surrounding host tissue by cells that 
originated from the primary tumor, followed by intravasation in blood and lymphatic vessels, 
ultimately leading to the dissemination of tumor cells.36 E-cadherin and EpCAM mediate cell-cell 
adhesion, and the downregulation or loss-of-function of these proteins enables cells to escape 
from solid tumors.19 E-cadherin and/or EpCAM are not necessarily expressed in all tumor cells; 
therefore, metastatic tumor cells might not be detected in some tissues. Furthermore, the majority 
of metastatic lobular breast cancer cells, which lack E-cadherin expression, will not be detected 
using a specific anti-E-cadherin probe, even though lobular breast cancer cells are more likely to 
invade ovarian tissue compared to cells derived from ductal carcinomas.37-38 
As mentioned above, we considered tumor cell membranes positive if they showed 
immunoreactivity of any intensity. As a result, some tumor cells might be more positive than 
others for the investigated markers. Yet, for NIRF imaging, the staining intensity is less important 
as long as a significant tumor-to-background-ratio can be achieved.
None of the premenopausal ovaries in our cohort had positive staining in either the stromal cells 
or the ovarian surface epithelium. However, all markers (except CEA and uPAR) were expressed 
on epithelial cells in inclusion cysts. Consequently, conjugating antibodies against these markers 
to a NIR fluorophore will illuminate invasive breast cancer cells in the ovary, as well as inclusion 
cysts. Because inclusion cysts might differ from metastatic breast cancer cells with respect to their 
fluorescent configuration, it might be possible to distinguish between these structures. The same 
strategy might be used to distinguish granulosa cells from primary follicles that express E-cadherin. 
In addition, full-field optical coherence tomography (FF-OCT), a non-invasive imaging technique 
that mimics conventional histopathology, might be very useful. In the field of dermatological 
oncology, FF-OCT has already been proven capable of visualizing sebaceous glands and adipose 
tissue surrounding hair follicles as well as small malignant skin tumors.39 On high magnification, 
fine architectural details on the subcellular level can be recognized. Therefore, it is expected that 
FF-OCT will also be able to distinguish inclusion cysts from metastatic tumor cells in ovarian tissue. 
One strength of our study is that we examined the expression of tumor markers in tumor 
tissues obtained from young breast cancer patients who met the criteria for ovarian tissue 
cryopreservation. Moreover, only biologically active ovaries were analyzed, giving the results 
clinical relevance, as ovarian tissue is generally cryopreserved before ovarian failure has occurred. 
On the other hand, this study has some limitations that merit discussion. First, a relatively 
small sample size was examined. However, normal ovarian tissue from premenopausal patients is 
not readily available. We excluded ovaries that were removed due to the presence of a BRCA gene 
mutation, as such samples could contain primary ovarian tumor cells,40 that express the markers 
investigated in this study. To be certain, we also excluded ovaries from breast cancer patients 
with unknown mutation status. At the LUMC, normal ovarian tissue from premenopausal breast 
cancer patients was exclusively available from BRCA mutation carriers or women with unknown 
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this study. Malignant cells may also be present in ovaries that were removed due to endometrial 
carcinoma, uterine sarcoma, cervical squamous cell carcinoma, or contralateral ovarian carcinoma; 
however, the risk of false-positive results was relatively low in our cohort, as all primary tumors 
were diagnosed at an early stage and the lymph nodes in these patients were clear. Second, the 
expression of the markers was evaluated on primary invasive breast tumors, since a substantial 
cohort consisting of ovarian tissues containing breast cancer metastases is scarce. Finally, we 
examined the expression of tumor markers in relatively small tumor cores using a TMA approach. 
However, the TMA technique is considered an accurate method for examining protein expression 
in breast cancer tissues.41 
Recently, the intraoperative use of tumor-targeted fluorescent imaging yielded a high tumor 
identification rate and enabled the surgeon to detect metastases that could not be detected 
by visual observation.42 For our purpose, tumor-specific NIRF probes could be administered 
intravenously prior to oophorectomy, after which the removed ovary is dissected into cortical 
ovarian strips. Detailed fluorescent images could then be obtained using multiphoton microscopy, 
which provides an inherent submicron spatial resolution that allows revelation of subcellular details 
with reduced phototoxicity and photobleaching.43-44 Because the NIRF signal lies beyond the red 
end of the visible spectrum, the signal has enhanced tissue penetration, enabling the identification 
of fluorescently labeled tumor cells that are located deep within the tissue. Moreover, the low 
autofluorescence of the tissue at the emission wavelength of the probe provides a high tumor-to-
background ratio.45 Because of these features and the fact that cortical ovarian fragments can be 
imaged from both the upper and lower side, thereby increasing the imaging depth even further, 
NIRF imaging is a promising technique for detecting tumor cells in cortical ovarian strips up to 2 
mm in thickness. 
In conclusion, we report the identification of tumor markers that may serve as a target for 
detecting breast cancer cells in ovarian tissue using robust imaging techniques such as NIRF 
imaging. Based on our analysis, E-cadherin is likely the most suitable target for designing a tumor-
specific probe. Further research will focus on examining the expression of these markers on breast 
cancer metastases in ovaries, refining methods to distinguish breast cancer cells from ovarian 
inclusion cysts, and examining the clinical feasibility of applying NIRF imaging to the field of 
fertility preservation. 
Ethics approval
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Abstract
Background
Autotransplantation of frozen-thawed ovarian tissue is a method to preserve ovarian function 
and fertility in patients undergoing gonadotoxic therapy. In oncology patients, the safety cannot 
yet be guaranteed, since current tumor detection methods can only exclude the presence of 
malignant cells in ovarian fragments that are not transplanted. We determined the need for a 
novel detection method by studying the distribution of tumor cells in ovaries from patients with 
breast cancer. Furthermore, we examined which cell-surface proteins are suitable as a target for 
non-invasive tumor-specific imaging of ovarian metastases from invasive breast cancer. 
Methods 
Using the nationwide database of the Dutch Pathology Registry (PALGA), we identified a cohort 
of 46 women with primary invasive breast cancer and ovarian metastases. The localization and 
morphology of ovarian metastases were determined on hematoxylin-and-eosin-stained sections. 
The following cell-surface markers were immunohistochemically analyzed: E-cadherin, epithelial 
membrane antigen (EMA), human epidermal growth receptor type 2 (Her2/neu), carcinoembryonic 
antigen (CEA), αvβ6 integrin and epithelial cell adhesion molecule (EpCAM). 
Results
The majority of ovarian metastases (71%) consisted of a solitary metastasis or multiple distinct 
nodules separated by uninvolved ovarian tissue, suggesting that ovarian metastases might 
be overlooked by the current detection approach. Combining the targets E-cadherin, EMA and 
Her2/neu resulted in nearly 100% detection of ductal ovarian metastases, whereas the combination 
of EMA, Her2/neu and EpCAM was most suitable to detect lobular ovarian metastases. 
Conclusion
Examination of the actual ovarian transplants is recommended. A combination of targets is most 
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Introduction
Cryopreservation of ovarian tissue is the only option to preserve fertility and restore ovarian activity 
in prepubescent girls and women who cannot postpone the start of adjuvant chemotherapy.1 
Although autotransplantation of frozen-thawed cortical ovarian tissue has resulted in more 
than 86 live births worldwide,2 this method has not yet been endorsed by the American Society 
for Reproductive Medicine (ASRM).3 One of the reasons that the ASRM committee has put 
forward is that the safety of the procedure has not been substantiated in patients with cancer. 
Cortical ovarian tissue may contain malignant cells that could lead to reseeding of cancer upon 
autotransplantation. This risk of reintroducing malignant cells cannot be eliminated, since the 
current tumor detection methods (e.g. PCR, immunohistochemistry) jeopardize the ovarian 
tissue’s viability.4 These methods can therefore only be used to examine cortical ovarian strips that 
are not transplanted. Hence, the presence of tumor cells in the actual ovarian autografts remains 
questionable.
Whether the current approach for tumor detection is accurate depends on the distribution of 
metastatic tumor cells in the ovarian tissue.5,6 If tumor cells are diffusely dispersed throughout the 
ovary, examination of one or two cortical ovarian strips might be sufficient. By contrast, if tumor 
cells are confined to a specific area in the ovarian cortex, this approach is inadequate. Then, 
cortical ovarian strips that are examined may turn out to be devoid of tumor cells whereas ovarian 
fragments that harbor metastases may be transplanted, possibly resulting in cancer relapse. 
The implementation of a detection method that allows examination of the cortical ovarian 
strips that will be transplanted, will significantly reduce the risk of transferring malignant cells. 
Near-infrared fluorescence (NIRF) imaging might be an appropriate approach, as this technique 
discriminates malignant cells from non-malignant tissue in real time while leaving the tissues 
viable.7 A NIRF probe consists of a fluorophore that emits light in the near-infrared spectrum (λ = 
700-900 nm) and an antibody or peptide with high affinity for a protein expressed specifically at 
the cell surface of tumor cells.8,9 
In order to use tumor-specific imaging to exclude malignant cells in cortical ovarian autografts, 
tumor markers should be identified that are present at the cell surface of ovarian metastases. Since 
a substantial proportion of patients who undergo ovarian tissue cryopreservation is diagnosed 
with breast cancer,10-12 we tested a panel of cell-surface markers known to be expressed by 
breast cancer cells, including E-cadherin,13 epithelial membrane antigen (EMA, also known as 
MUC1),14,15 human epidermal growth factor receptor type 2 (Her2/neu),16,17 carcinoembryonic 
antigen (CEA),18 αvβ6 integrin,19 and epithelial cell adhesion molecule (EpCAM).20-22 The markers 
cytokeratin CAM 5.2, gross cystic disease fluid protein-15 (GCDFP15), Wilms’ tumor antigen-1 
(WT1), mammaglobin 1, and cytokeratin 7 (CK-7), which were used by Sánchez-Serrano et al.23 
and Rosendahl et al.,6 were excluded, as they are not expressed at the cell surface and therefore 
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In this study, we assessed the distribution of breast tumor cells in ovarian tissues from patients 
with ovarian metastases and determined which cell-surface proteins are suitable as a target for 
tumor-specific imaging of ovarian metastases derived from invasive breast cancer. Because it is 
crucial to select a target prior to the administration of the NIRF probe, we also examined whether 
invasive breast cancer tissue can be used to predict the most suitable target for the detection of 
ovarian metastases in a particular patient.
Methods
Patient selection and tissue collection
Via a nationwide search performed by PALGA, the Dutch histopathology and cytopathology 
network that encompasses all pathology laboratories within the Netherlands,24 a source population 
was compiled. This source population consisted of all patients who were diagnosed with primary 
invasive breast cancer at age < 41 years in the period 2000-2010 and who subsequently underwent 
an oophorectomy for any reason. From this source population, all patients who had histologically 
confirmed ovarian metastases from primary invasive breast cancer, were selected. Following 
this, hematoxylin-and-eosin (H&E) stained tissue sections and formalin-fixed paraffin-embedded 
(FFPE) tissue samples from the primary invasive breast tumors and their corresponding ovarian 
metastases were requested from pathology laboratories. If patients had locally recurrent breast 
cancer or a second primary invasive breast tumor prior to oophorectomy, FFPE tissue samples 
from these tumors were also requested. Clinical data were extracted from the patient’s files after 
approval by the medical ethical committee of the Leiden University Medical Center (protocol 
number P14.106) and the local medical ethical committees of the participating hospitals. 
 
Distribution of breast cancer cells in the ovary
The distribution of breast cancer cells in ovarian tissues was evaluated using the original H&E-
stained sections by assessment of their localization and morphological features. The localization 
of breast cancer cells was determined as confined to the ovarian cortex and/or medulla. With 
respect to morphology, breast cancer cells were classified as a solitary metastasis, multiple distinct 
nodules separated by uninvolved ovarian tissue, or diffuse seeding without any discernable 
pattern. 
Immunohistochemistry
Immunohistochemistry was performed on 4-μm thick FFPE sections of primary invasive breast 
cancers, locally recurrent breast cancers (if applicable) and their corresponding ovarian metastases. 
The tissue sections were deparaffinized in xylene, dehydrated in a stepwise series of graded alcohol 








































Morphological and phenotypical features of ovarian metastases in breast cancer patients  |  67
4
hydrogen peroxide for 20 minutes, heat-induced antigen retrieval was performed by placing the 
slides in EnVision Flex Target Retrieval Solution high pH (pH 9.0; E-cadherin, EMA) or in the same 
solution but low pH (pH 6.0; Her2/neu) in PT Link (Dako, Denmark). EpCAM and αvβ6 integrin 
epitopes were unmasked by 30-minute incubation with 0.125% trypsin and 0.4% pepsin, 
respectively, at 37° C. For CEA, no antigen retrieval was required. The sections were incubated 
overnight in a humidified chamber at room temperature with primary antibodies against Her2/
neu (ERBB2, rabbit polyclonal, Dako), E-cadherin (NCH38, mouse monoclonal, Dako), EpCAM 
(323/A3, mouse monoclonal, provided by the Department of Pathology, LUMC, the Netherlands), 
CEA (A0115, rabbit polyclonal, Dako), αvβ6 integrin (6.2A1, mouse monoclonal, Cell Essentials), 
or EMA (E29, mouse monoclonal, Dako); all primary antibodies were used at their predetermined 
optimal dilution. After incubation with primary antibodies, the sections were rinsed with PBS, 
incubated with secondary antibodies (anti-mouse or anti-rabbit EnVision; Dako) for 30 minutes, 
and visualized using liquid DAB+ substrate buffer (Dako). The sections were counterstained 
with Mayer’s hematoxylin solution, dehydrated, and mounted with Pertex (Leica Microsystems, 
Germany). For each immunostain, tissues expressing the antigen of interest were included as a 
positive control. Tissue sections stained without application of the primary antibody were used 
as a negative control. 
Immunofluorescent triple staining
For immunofluorescent triple staining, the three most highly expressed markers for ductal and 
lobular ovarian metastases were chosen. In brief, FFPE sections of these ovarian metastases were 
deparaffinized as described above. Antigen retrieval was performed by placing the slides in 
EnVision Flex Target Retrieval Solution high pH (pH 9.0; Dako). Primary antibodies for ductal ovarian 
metastases: E-cadherin, EMA and Her2/neu. Primary antibodies for lobular ovarian metastases: 
EMA, Her2/neu and EpCAM. Secondary antibodies were all isotype-specific antibodies with Alexa 
Fluorochromes (LifeTechnologies, USA): anti-mouse IgG1-AlexaFluor488 (E-cadherin and EpCAM; 
green), anti-mouse IgG2a-AlexaFluor647 (EMA; red) and anti-rabbit-AlexaFluor546 (Her2/neu; 
orange). Sections were mounted with Vectashield containing DAPI (Vector Laboratories, USA). 
Primary invasive breast tumor samples that showed positive expression for all markers in previous 
experiments were used as a positive control. Tissue sections stained without application of 
primary antibodies were used as a negative control.
Image capture and quantification of immunoreactivity
The immunohistochemically stained slides were digitized using an IntelliSite Pathology 
Ultra-Fast Scanner 1.6 RA (Philips, The Netherlands). The percentage of malignant cells with 
immunohistochemically positive stained membranes were scored by two independent observers 
(I.P. and M.S.). In case of discrepancy, the observers reached consensus regarding a final score. 
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intensity. The immunofluorescent stained slides were digitized using a Pannoramic MIDI digital 
slide scanner (3DHistech, Hungary). The percentage of malignant cells with immunofluorescent 
positive stained membranes were also scored by two independent observers (I.P. and B.H.).
Statistical analysis
Statistical analysis was performed using SPSS version 23.0 (IBM, Armonk, NY). Inter-observer 
agreement was calculated using the Pearson correlation coefficient. Scatter plots based on 
generalized estimating equations analysis were made to determine whether invasive breast cancer 




Patient selection and clinicopathological characteristics
According to the PALGA registry, 2648 patients were diagnosed with primary invasive breast cancer 
at age < 41 years in the period 2000-2010 in the Netherlands who subsequently underwent an 
oophorectomy (Figure 1). Among these patients, 63 patients had ovarian metastases. Of these 63 
patients, tumor tissue samples were available from 46 patients. These 46 patients were included 
in this study.  
Figure 1. Patient selection and composition of the study population
The source population was compiled by the Dutch histopathology and cytopathology network. The exclusion 
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The clinicopathological characteristics of the 46 patients are shown in Table 1. The median age at 
the time of diagnosis was 36.5 years (range 28-40 years). Thirty-six patients were diagnosed with 
invasive ductal breast cancer and five patients were diagnosed with invasive lobular breast cancer. 
The remaining five patients had invasive ductolobular breast cancer. Almost 15% of patients 
had distant metastases outside the ovary at the time of breast cancer diagnosis. The median 
time between this diagnosis and oophorectomy was 41.9 months (range 0.3-141.8 months). In 
the majority of cases, the oophorectomy was done prophylactically or therapeutically because 
of breast cancer. In only one fourth of cases, the ovaries were removed because they appeared 
abnormal on ultrasound. Further patient and tumor characteristics are presented in Table 1.
Table 1. Clinicopathological characteristics of patients with primary invasive breast cancer and 
ovarian metastases
Clinicopathological characteristics N = 46 %
Age at diagnosis of breast cancer, years - median (range) 36.5 (28 - 40) -
BRCA gene mutation
No 8 17.4
Yes, BRCA 1 1 2.2
Yes, BRCA 2 0 0.0
Unknown 37 80.4




Most extensively performed breast surgery
Needle biopsy 4 8.7
Breast conserving surgery 15 32.6
Mastectomy 27 58.7







































































Age at diagnosis of ovarian metastases, years - median (range) 40.0 (31 - 51) -
Time between breast cancer and ovarian metastases, months - 
median (range)
41.9 (0.3 - 141.8) -
Recurrent disease prior to oophorectomy
No 15 32.6
Yes, locoregional recurrence 12 26.1
Yes, distant recurrence 19 41.3
Type of ovarian surgery
Unilateral oophorectomy 0 0.0
Bilateral oophorectomy 46 100.0
Indication for oophorectomy
Prophylactic because of breast cancer 9 19.6
Therapeutic because of breast cancer 25 54.3
Abnormal ovaries on ultrasound 12 26.1
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Localization and morphology of ovarian metastases
Of the 46 patients, 29 patients had metastases in both ovaries (Table 1). Therefore, the total 
number of ovaries that contained metastases was 75. The localization and morphology of these 
75 ovarian metastases are shown in Table 2. In 14 ovaries (19%) the metastases seemed confined 
to the cortex, whereas in 53 ovaries (70%) both the cortex and medulla were involved (Table 
2). In half of the ovaries multiple distinct nodules were seen, while in twenty percent a solitary 
metastasis was found. Diffuse seeding without any discernable pattern was observed in 29% of 
ovaries. Figure 2 shows examples of these morphological features. 
Table 2. Localization and morphology of ovarian metastases derived from patients diagnosed with 
invasive breast cancer
Histological features Ovarian metastases
    N = 75   %




Morphology of ovarian metastases    
Solitary metastasis 15 20.0
Multiple distinct nodules separated by uninvolved      
ovarian tissue
38 50.7
Diffuse seeding without any discernable pattern 22 29.3




Of the 46 patients who were diagnosed with invasive breast cancer and ovarian metastases, 29 patients had 
metastases in both ovaries. The total number of ovaries that contained metastases was 75.
Figure 2. Localization of ovarian metastases derived from patients diagnosed with invasive breast 
cancer
Three examples are shown: (a) a solitary metastasis, (b) multiple distinct nodules separated by uninvolved 
ovarian tissue and (c) diffuse seeding without any discernable pattern. In order to clearly display the solitary 
metastasis in (a) and the multiple distinct nodules in (b), a green line is drawn that delineates the metastases 
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Expression of cell-surface proteins
Immunohistochemistry was performed to determine which cell-surface proteins are suitable as 
a target for tumor-specific imaging of ovarian metastases from invasive breast cancer. A strong 
correlation was observed between the scoring results obtained by the two observers; the median 
R2 was 0.846 (range 0.640-0.960). Representative examples of the immunohistochemical 
stainings of the invasive breast tumor samples and their corresponding ovarian metastases are 
shown in Supplementary Figure S1. 
Table 3 shows the mean percentage of positive tumor cells for the investigated markers in 
primary and recurrent invasive breast tumors and their ovarian metastases. Since loss of expression 
of the cell-adhesion molecule E-cadherin frequently occurs in invasive lobular carcinomas,25 the 
expression of markers was examined by histological subtype. With respect to invasive ductal 
carcinomas, E-cadherin, EMA and Her2/neu were most suitable; these markers were present in 
91, 84 and 81% of metastatic breast tumor cells in the ovaries, respectively. In invasive lobular 
carcinomas, the mean percentage of positively stained breast tumor cells in the ovaries was 
highest for EMA, Her2/neu and EpCAM; specifically, 64, 74 and 68%, respectively. In patients 
diagnosed with ductolobular breast cancer, targeting EMA would result in the detection of 99% 
of disseminated breast cancer cells in the ovaries. 
Table 3. Immunohistochemical expression of the investigated markers in invasive breast tumors 
and their corresponding ovarian metastases
Marker % of positive tumor cells in 
invasive ductal carcinoma
% of positive tumor cells in 
invasive lobular carcinoma
% of positive tumor cells in 
invasive ductolobular carcinoma


















  Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
E-cadherin 91 18 91 20 9 23 0 0 73 35 51 41
EMA 86 23 84 24 86 32 64 32 97 6 99 2
Her2/neu 76 35 81 31 88 26 74 26 80 34 67 38
CEA 56 40 57 39 73 32 59 26 62 32 56 33
αvβ6 integrin 51 40 45 39 54 35 38 28 45 30 29 35
EpCAM 36 42 38 39 38 46 68 26 19 29 35 29
SD = standard deviation 
The mean percentages of immunohistochemically positive stained tumor cells are subdivided by histological 
subtype. Tumor cell membranes were considered positive if they showed immunoreactivity of any 
intensity. EMA, epithelial membrane antigen; Her2/neu, human epidermal growth receptor type 2; CEA, 
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Correlation between the expression of cell-surface proteins in invasive breast tumors 
and their corresponding ovarian metastases
In patients diagnosed with ductolobular breast cancer, the expression of EMA in the invasive 
breast tumors was in accordance with the expression in their corresponding ovarian metastases, 
showing small standard deviations (Table 3). Therefore, EMA would be the most suitable target to 
detect ductolobular ovarian metastases. By contrast, in patients diagnosed with ductal or lobular 
breast cancer large variations in expression among tumors were found. To understand whether 
in these patients invasive breast tumor tissues can be used to predict the most suitable target for 
the detection of ovarian metastases in an individual patient, scatter plots were made (Figure 3). 
For each patient, the percentage of positive tumor cells in primary and locally recurrent breast 
tumors (if applicable) was set against the percentage of positive tumor cells in their corresponding 
ovarian metastases. No correlation between these expressions could be substantiated, showing 
that ductal and lobular breast tumor tissues cannot be used to predict the most pertinent marker 
for the detection of their corresponding ovarian metastases.
Detection of ovarian metastases by a combination of markers
Figure 3 also shows that the use of one marker would not always be sufficient to detect all 
metastatic ductal or lobular breast cancer cells in the ovaries. The use of one marker (E-cadherin, 
EMA or Her2/neu) would result in the detection of 100% of tumor cells in 44 out of 58 ductal 
ovarian metastases (data not shown). With respect to the lobular subtype, EMA, Her2/neu or 
EpCAM was present in 100% of tumor cells in 4 out of 10 ovarian metastases. 
To investigate whether a combination of markers would enable the detection of 100% of 
tumor cells in all ductal and lobular ovarian metastases, an immunofluorescent triple staining 
was performed. By combining the three most suitable markers for the ductal (E-cadherin, EMA 
and Her2/neu) and lobular (EMA, Her2/neu and EpCAM) subtypes, 100% tumor cell detection 
was accomplished in 53 out of 58 ductal ovarian metastases and in 7 out of 10 lobular ovarian 
metastases. Hence, cells within ovarian tissues that show membranous positivity for any of the 
three markers mentioned will be deemed malignant. In the remaining five ductal and three lobular 
ovarian metastases, the mean percentage of undetected metastatic cells was 5% (no range) and 
25% (range 10-40), respectively. Figure 4 shows a representative image of the immunofluorescent 
triple staining in a lobular ovarian metastasis, in which the combination of EpCAM, EMA and 
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Figure 4. Detection of ovarian metastases by a combination of markers
Representative image of a lobular ovarian metastasis stained with DAPI counterstain and triple 
immunofluorescence for EpCAM (a), EMA (b), Her2/neu (c), and the three stainings combined (d). The solid 
arrow indicates tumor cells that are positive for EpCAM, but negative for EMA and Her2/neu. The dashed 
arrow indicates tumor cells that are positive for Her2/neu, but negative for EpCAM and EMA. Scale bars 
represent 100 μm. EpCAM, epithelial cell adhesion molecule; EMA, epithelial membrane antigen; Her2/neu, 
human epidermal growth receptor type 2.
Discussion
One of the purposes of the present study was to examine the histological features of ovarian 
metastases in breast cancer patients to evaluate the current tumor detection approach4 in ovarian 
tissues considered for autotransplantation. We found that 71% of ovarian metastases consisted 
of a solitary metastasis or multiple distinct nodules separated by uninvolved ovarian tissue. These 
findings suggest that tumor cells might have been missed if the current tumor detection approach 
would have been used. The patients included in this study however, underwent oophorectomy 
after a median time interval of 42 months. In patients undergoing ovarian tissue cryopreservation 
an oophorectomy is performed soon after cancer diagnosis. In these patients, disseminated tumor 
cells may not yet have outgrown into overt metastases and may appear as micrometastases 
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greater. We therefore recommend examination of the actual ovarian autografts on the presence 
of malignant cells prior to autotransplantation. 
In our study, merely 63 out of 2648 patients (2.4%) who were diagnosed with primary invasive 
breast cancer at age < 41 years had ovarian metastases. For the determination of suitable targets 
for NIRF imaging, it might have been relevant to focus on malignancies with a higher risk of 
ovarian contamination in the actual patient population, for instance leukemia.28-30 Nonetheless, 
breast cancer can be perfectly used as a starting point to investigate whether NIRF imaging is 
feasible for the detection of ovarian metastases. 
Considering the expression of Her2/neu in primary invasive breast cancers and ovarian 
metastases a high percentage of Her2/neu positive tumor cells (67-88%) was found, as we 
considered tumor cell membranes positive if they showed immunoreactivity of any intensity. This 
is in contrast to the diagnostic setting, where Her2/neu overexpression is determined because 
of its potential prognostic value.17,31 We applied a lower cut-off point, because for NIRF imaging 
the staining intensity is less important as long as a significant tumor-to-background-ratio can 
be achieved. In the NIR spectrum, non-specific fluorescence background signal is substantially 
decreased compared to wavelengths lower than NIR.8 Hence, since ovarian stromal cells do not 
immunohistochemically express Her2/neu,32 Her2/neu-targeting NIRF probes will detect metastatic 
breast cancer cells within ovarian tissues if these cells show immunohistochemical reactivity.
In individual patients, no correlation was found between the expression of the investigated 
markers in breast tumors and their corresponding metastases in the ovary. This might be due 
to the fact that breast cancer is known as a heterogeneous disease17 or be in line with the 
hypothesis that disseminated tumor cells autonomously evolve from the primary tumor.33 For the 
clinical application of these markers there should not be an obstacle, since a combination of three 
markers enhances the ability to detect breast tumor cells in ductal and lobular ovarian metastases. 
Furthermore, only the histological subtype of the invasive breast tumor needs to be known to 
determine which combination of markers is pertinent for the detection of the corresponding 
ovarian metastases, making the selection of suitable NIRF probes simple and straightforward.
For the non-invasive detection of metastases in the actual ovarian autografts by tumor-specific 
imaging, NIRF probes could be administered intravenously, after which the removed ovary is 
dissected into cortical ovarian strips. Subcellular detailed fluorescent images of tumor cells within 
ovarian autografts could then be obtained by multiphoton microscopy.34 Beside breast cancer 
cells, inclusion cysts will likely also be illuminated by NIRF imaging, as we previously showed 
that in normal ovaries, all markers (except CEA) were expressed on epithelial cells in inclusion 
cysts.32 Nevertheless, we additionally demonstrated that full-field optical coherence tomography 
(FF-OCT), which creates histology-like images without the need for tissue manipulation, can 
be perfectly used to differentiate between inclusion cysts and metastases in the ovary.35 On a 
tomographic FF-OCT image, an inclusion cyst is characterized by a thin dark outer layer and lack 
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present as ‘web-like’ structures in which tumor cells appear light gray. Metastatic lesions derived 
from primary invasive lobular carcinomas often show an Indian file pattern, defined as infiltrating 
single rows of cells.36 Since ovarian inclusion cysts are separately identifiable within the ovarian 
parenchyma,32 a distinction between these structures can also be made. In addition, FF-OCT 
and NIRF imaging might be combined to enhance their sensitivity and specificity rates, as both 
methods are noninvasive. 
The a priori probability that other benign epithelial ovarian abnormalities will be detected 
by our panel of cell-surface markers is low, since ovaries that present as an adnexal mass on 
preoperative ultrasonography are generally not used for ovarian tissue cryopreservation. In case 
primary ovarian cancer cells are present, these cells will be detected as E-cadherin,37 EMA,38 and 
EpCAM39 are virtually always expressed in ovarian cancer, and approximately 33% of primary 
ovarian carcinomas show Her2/neu amplification.40
Conclusion
In conclusion, we showed that in young breast cancer patients with ovarian metastases, metastatic 
breast tumor cells may be confined to a specific area in the ovarian cortex. A non-invasive tumor 
detection technique by which cortical ovarian fragments that are transplanted can be examined, 
is recommended to minimize the risk of reintroducing metastatic tumor cells by ovarian 
tissue autotransplantation in breast cancer patients. NIRF imaging is a promising technique to 
discriminate malignant from benign tissues while leaving the examined tissues vital. Our research 
opens a new avenue for the development of tumor-specific NIRF probes that can be used for 
non-invasive detection of breast cancer metastases in ovarian tissues prior to autotransplantation. 
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Supplementary Figure S1. Immunohistochemical expression of tumor markers in invasive breast 
tumors and their corresponding ovarian metastases
Arrows indicate tumor cells that show heterogeneous expression of markers. Scale bars represent 100 
μm. EMA, epithelial membrane antigen; Her2/neu, human epidermal growth receptor type 2; CEA, 
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Supplementary Table S2. List of participating hospitals
An overview is given of the treatment hospitals that participated in the study.
Amphia hospital







Leiden University Medical Center
Lievensberg hospital








St. Lucas Andreas hospital
St. Franciscus gasthuis
University Medical Center Groningen
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Abstract
Purpose
Autotransplantation of ovarian tissue can be used to restore fertility in cancer patients following 
gonadotoxic treatment. Whether this procedure is safe remains unclear, as current tumor detection 
methods render the ovarian tissue unsuitable for transplantation. Full-field optical coherence 
tomography (FF-OCT) is an imaging modality that rapidly produces high-resolution histology-
like images without the need to fix, freeze, or stain the tissue. In this proof-of-concept study, 
we investigated whether FF-OCT can be used to detect metastases in ovarian tissue, thereby 
increasing the safety of ovarian tissue autotransplantation. We also evaluated whether cortical 
ovarian tissue and follicles remain viable following FF-OCT imaging. 
Experimental design
Formalin-fixed, paraffin-embedded tissue samples were obtained from seven normal ovaries 
and fourteen ovaries containing metastases and/or micrometastases. These samples were 
deparaffinized and imaged using FF-OCT. The FF-OCT images were then compared to 
corresponding hematoxylin-and-eosin-stained tissue sections. Finally, we examined the effect of 
FF-OCT imaging on the viability of ovarian tissues and follicles in fresh bovine ovarian tissue using 
a glucose uptake and neutral red staining, respectively.
Results
FF-OCT illustrated both normal structures and metastases in ovarian tissue within minutes. 
Primordial follicles were readily identifiable. Finally, tissues and follicles remained viable following 
FF-OCT imaging for up to 180 and 60 minutes, respectively.
Conclusion
FF-OCT imaging is a promising method for the non-invasive detection of metastases, including 
micrometastases, in ovarian tissue. Moreover, this method facilitates the selection of cortical 
ovarian tissue with the highest density of primordial follicles, potentially increasing the likelihood 
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Introduction
Although advanced screening methods and novel treatment modalities represent a great leap 
forward in the treatment of cancer leading to substantially increased survival rates, new concerns 
have arisen as a consequence of these remedies, particularly among young women. Specifically, 
chemotherapy and/or pelvic radiotherapy can lead to premature ovarian failure due to accelerated 
follicle loss.1 Therefore, preserving female reproductive capability is extremely important and has 
high priority. Currently, the most established fertility preservation procedures include freezing of 
embryos and/or oocytes. In addition, cryopreservation and subsequent autotransplantation of 
cortical ovarian tissue has become more prevalent. Because this method obviates the need for 
hormonal stimulation, it is deemed particularly suitable for prepubescent girls and young women 
who cannot delay the start of adjuvant therapy.2 Autotransplantation of frozen-thawed ovarian 
tissue has been shown to restore ovarian activity in 93% of cases, and to date 60 resulting live 
births have been reported worldwide.3-4 Despite these encouraging statistics, the safety of this 
procedure cannot yet be ascertained for certain types of cancer, as there is a potential risk of 
occult ovarian involvement at the time of tissue harvesting.5-6 Due to the fact that the current 
tumor detection methods (e.g. histology, PCR analysis) render the tissue fragment unsuitable for 
transplantation, the presence of disseminated tumor cells can only be determined in the ovarian 
tissues that are ultimately not transplanted. Consequently, tumor cells that have metastasized 
to the actual ovarian autografts can be reimplanted, thereby potentially re-establishing cancer 
in the recipient. Previous reports have documented recurrences following autotransplantation 
in a patient diagnosed with breast cancer7 and a patient diagnosed with cervical cancer.8 
However, whether these recurrences can be directly attributed to autotransplantation remains 
unclear. On the other hand, it is entirely plausible that malignant cells were reintroduced by 
autotransplantation in a patient with a granulosa cell tumor.9
To minimize the likelihood of reintroducing tumor cells, a technique that is capable of 
discriminating malignant from healthy tissues while leaving the examined tissues unaffected is 
needed. Full-field optical coherence tomography (FF-OCT) is a promising new imaging modality 
that satisfies these key criteria. Importantly, FF-OCT rapidly generates high-resolution histology-
like images without the need to fix, freeze, or stain the tissue.10 With FF-OCT, the image contrast 
is based on the light-scattering properties of different structures in the tissue. FF-OCT has already 
been used successfully to detect tumors in a wide variety of human tissues, including prostate,11 
skin,12 brain,13 lung,14 and kidney15 samples. 
In this proof-of-concept study, we investigated whether FF-OCT can be used to visualize 
normal structures as well as metastases—including micrometastases—in human ovarian tissue. 
In addition, we evaluated whether cortical ovarian tissue and preantral follicles remain viable 
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Materials and methods
Human ovarian tissue specimens
Formalin-fixed, paraffin-embedded (FFPE) specimens of normal ovaries obtained from 
premenopausal women who underwent prophylactic bilateral oophorectomy because of the 
presence of a BRCA gene mutation in the period 2001-2012 were selected from the archives 
of the Department of Pathology at the Leiden University Medical Center (LUMC). Patients who 
were previously treated with chemotherapy or used oral contraceptives prior to oophorectomy 
were excluded in order to ensure that only functionally active ovaries were included in the 
study. In addition, via a nationwide search performed by PALGA, the Dutch histopathology 
and cytopathology network and archive that covers all pathology laboratories within the 
Netherlands,16 FFPE specimens of ovarian metastases were collected from women with primary 
invasive breast cancer at age < 41 years in the period 2000-2010. Ovarian metastases derived 
from other primary malignancies in which ovarian tissue cryopreservation is performed were 
collected from the archives of the Department of Pathology at the LUMC. Hematoxylin-and-eosin 
(H&E) stained tissue sections were obtained and digitized using an IntelliSite Pathology Ultra-Fast 
scanner 1.6 RA (Philips, Eindhoven, the Netherlands). Following this, the entire FFPE tissue blocks 
were deparaffinized and imaged using FF-OCT. 
All patient samples and clinical data were handled in accordance with the medical ethics 
guidelines described in the Code of Conduct for the Proper Secondary Use of Human Tissue of 
the Dutch Federation of Biomedical Scientific Societies (FMWV).17
Bovine ovarian tissue specimens
Intact bovine ovaries were collected at an abattoir within 15 minutes after slaughtering and 
immediately transported on ice to the laboratory at the LUMC. The average transport time was 
20 minutes. At the laboratory, each ovary was cut into two halves, and the medulla was removed. 
The remaining cortex was trimmed to a thickness of 1-2 mm and subsequently cut into fragments 
measuring 2-3 mm or 5-10 mm in diameter for a glucose uptake assay or a neutral red staining, 
respectively. Bovine cortical ovarian fragments were stored until imaging (ranging from 0 to 180 
minutes) in 24-wells plates at 4°C. Each well contained 1.5 ml DMEM culture medium (Lonza 
BioPharma; Visp, Switzerland) supplemented with 10% FCS (Gibco, Thermo-Fisher; Waltham, 
MA) and 1% penicillin/streptomycin (MP Biomedicals; Santa Ana, CA).
Full-field optical coherence tomography
A commercially available LightCT FF-OCT system (LLTech; Paris, France) was initially used in this 
study.18 During the course of the study, the LightCT scanner was upgraded to a newly developed 
FF-OCT system (LLTech), which is faster and can accommodate larger tissue samples. Both systems 
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with spectral width of 125 nm, and reference arm in the Linnik interferometric configuration.19-20 
The light reflected by the tissue interferes with the light reflected by the reference mirror, and the 
signal is then isolated from the scattered background light using a combination of four phase-
shifted interferometric images. The LightCT scanner, which was used for the viability experiments, 
uses a 150-Watt white halogen lamp as the light source and generates a 0.8 mm x 0.8 mm en 
face image (with a maximum field of view 25 mm in diameter using image mosaicking) at an 
image rate of 35 Hz. The newly developed FF-OCT system, which was used to image the human 
ovarian tissues, uses an LED lamp as the light source and generates a 1.3 mm x 1.3 mm en face 
image (with a maximum field of view 45 mm in diameter) at an image rate of 75 Hz.
Image acquisition was similar for the two systems. In brief, the tissue was placed in the 
sample holder. Deparaffinized ovarian tissue was covered with saline, whereas fresh ovarian 
tissue was covered with DMEM culture medium (Lonza BioPharma) supplemented with 10% 
FCS (Gibco, Thermo-Fisher) and 1% penicillin/streptomycin (MP Biomedicals). An optical window 
was positioned above the tissue, and the tissue was gently flattened against this window. A layer 
of silicone oil was then applied between the optical window and the microscope objective. A 
macroscopic image was obtained using a wide-field camera, followed by FF-OCT images, which 
were made en face. The field of view encompassed the entire cortical ovarian fragment. With 
respect to human ovarian tissues, images were taken at a depth of 0-20 µm to ensure the best 
possible correspondence with the histology images. Considering the bovine cortical ovarian 
fragments, images were taken up to a depth of 100 μm, as it was the maximum depth at which 
high resolution could be retained. The number of images taken in depth depended on the time 
that was needed to achieve the predefined imaging time for the viability tests (ranging from 0 to 
180 minutes). Both systems had 1.5 μm transverse resolution and 1 μm axial resolution.
Determining the viability of ovarian tissue using the glucose uptake assay
Bovine cortical ovarian tissue fragments measuring 2-3 mm in diameter were imaged using the 
LightCT scanner for 3, 10, 60, or 180 minutes. Fresh cortical ovarian samples that were not imaged 
served as a control, whereas cortical ovarian tissue samples in which cell death was induced by 
snap-freezing in liquid nitrogen served as a negative control. After imaging, the ovarian samples 
were transferred to 24-well plates for culturing. Each well was prepared in triplicate and contained 
three cortical ovarian samples in 1.5 ml DMEM culture medium (Lonza) supplemented with 10% 
FCS (Gibco, Thermo-Fisher) and 1% penicillin/streptomycin (MP Biomedicals). During culture, 
the medium was checked periodically for the presence of bacteria under a light microscope. The 
glucose content of the culture medium was measured using a blood-gas analyzer (Modular P 
Chemistry Analyzer; Roche Diagnostics, Indianapolis, IN). After four days in culture, the samples 
were weighed, and glucose consumption was measured and expressed per milligram of ovarian 
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Determining the viability of ovarian follicles using neutral red staining
The viability of preantral ovarian follicles was determined using a neutral red staining assay 
adapted from the protocol published by Kristensen et al.23 Fresh bovine cortical ovarian fragments 
were imaged in triplicate using the LightCT scanner for 3, 10, 60, or 180 minutes. These ovarian 
fragments were 5-10 mm in diameter and 1-2 mm thick. Fresh cortical ovarian fragments that 
were not imaged served as a control, and cortical ovarian tissue fragments in which cell death 
was induced by snap-freezing in liquid nitrogen served as a negative control. After imaging, the 
ovarian fragments were cut into small pieces. These pieces were placed in 15-ml conical tubes 
containing 5 ml preheated Serum-free Ultraculture medium (Lonza) supplemented with 1 mg/
ml collagenase type IA (Sigma-Aldrich, St. Louis, MO). During incubation, the cell suspensions 
were triturated through a 5-ml pipette to further disrupt the tissue. After incubation for 25 
minutes at 37°C, the samples were centrifuged at 2500 rpm for 5 minutes. The supernatants 
were poured off, and each pellet of cells was incubated for 1.5 hours at 37°C in 4.8 ml McCoy’s 
medium (Life Technologies, Carlsbad, CA) supplemented with 2 μl Albuman (200 g/L; Sanquin, 
Amsterdam, the Netherlands), 50 μl Insulin-Transferrin-Selenium (ITS-G; Life Technologies), 50 μl 
penicillin/streptomycin (MP Biomedicals), and 75 μl neutral red solution (3.3 g/L; Sigma-Aldrich). 
The number of red-colored (viable) and uncolored (non-viable) follicles in the partially dissolved 
ovarian tissue fragments were counted in ten high-power fields per specimen under a light 
microscope by two independent observers (I.P. and P.S.) who were blinded with respect to the 
samples.  
Statistical analysis
Statistical analysis was performed using SPSS version 23.0 (IBM, Armonk, NY). Inter-observer 
agreement was calculated using the Pearson correlation coefficient. A multivariate linear 
regression model was used to compute the mean difference in the glucose uptake of cortical 
ovarian biopsies between the various FF-OCT exposure times. The values were adjusted for 
the number of ovaries included. To investigate the effect of FF-OCT imaging on the viability of 
preantral follicles, we compared the proportions of viable preantral follicles between the various 
FF-OCT exposure times. 
Results
Human ovarian tissue specimens
FFPE tissue samples from seven normal ovaries (obtained from six premenopausal patients) and 
fourteen ovaries containing metastases and/or micrometastases (obtained from twelve patients) 
were deparaffinized and imaged using FF-OCT. In most cases, the FF-OCT images could be 
easily interpreted using the inverse setting. In this inverse setting, structures that reflect light the 








































Noninvasive detection of metastases and follicle density in ovarian tissue using full-field optical coherence tomography  |  91
5
Figure 1 shows representative FF-OCT images and corresponding histology images of the 
most clinically relevant structures in a normal ovary. The primordial follicles, which are small 
primary oocytes surrounded by a single layer of flattened granulosa cells,24 appear as either round 
or crescent-shaped white structures, depending on the level at which they were imaged (Figure 
1A-B). In primary follicles, the flat granulosa cells transform into a cuboidal structure and the zona 
pellucida forms between this layer and the oocyte. On the FF-OCT image, the oocyte appears 
somewhat darker than the zona pellucida, and the granulosa cells can be distinguished quite 
well (Figure 1C-D). Figure 1E-F shows a corpus rubrum, which is a small hemorrhage that forms 
immediately after ovulation. The corpus luteum is composed of an outer layer of smaller thecal-
lutein cells and an inner layer of larger granulosal-lutein cells. On the FF-OCT images, the densely 
packed thecal-lutein cells reflected more light than the granulosal-lutein cells, which reflected 
light to the same extent as the corpus rubrum (Figure 1G-H). The corpus albicans (Figure 1I-J) and 
corpus fibrosum (Figure 1K-L), which are masses of fibrous scar tissues that form when the oocyte 
is not fertilized, showed high levels of reflection due to their collagen content. Lastly, an inclusion 
cyst (Figure 1M-N) was identified by its thin dark outer layer and lack of interior structure. 
Figure 2A shows representative FF-OCT images of a sagittal section of an ovary containing 
micrometastases; this sample was derived from a primary invasive ductal breast carcinoma. Figure 
2B-C and Figure 2D-E show magnified views of micrometastases measuring 0.9 mm and 1.7 mm, 
respectively. These metastatic lesions could be distinguished clearly from the surrounding stromal 
cells, as the stromal cells reflected considerably more light than the lesions. On the FF-OCT 
images, these lesions have a ‘web-like’ architecture in which the tumor cells appear light gray. 
Furthermore, a distorted ovarian cortex architecture (Figure 2D) was often seen in the presence of 
disseminated tumor cells. Figure 3 shows metastatic lesions within ovarian tissues obtained from 
three individual patients. Figure 3A-B depicts a solitary metastasis that originated from an invasive 
ductal breast carcinoma; the FF-OCT image shows the microglandular proliferation. In Figure 3C-
D, the ovarian stroma is completely occupied by the metastatic lesion, which has a characteristic 
stromal component. The FF-OCT image of a metastasis originating from a primary endometrial 
carcinoma shows a typical cribriform morphology (Figure 3E), with good correspondence with the 
previously obtained H&E tissue section (Figure 3F). The morphological features of the remaining 
ten ovaries containing metastatic disease corresponded to those depicted in Figures 2 and 3. All 
types of normal ovarian features and metastatic lesions that were identified in the histology (H&E) 
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Figure 1. Example inverse FF-OCT images (left column) and corresponding histology images (right 
column) of normal ovarian tissues
The following normal ovarian structures are shown in the images: primordial follicles (A-B), a primary follicle 
(C-D), a corpus rubrum (E-F), part of a corpus luteum (G-H), a corpus albicans (I-J), a corpus fibrosum (K-L), 
and an inclusion cyst (M-N). In each image, the normal ovarian structures are indicated by an arrow. All but 
one primordial follicle were detected in the FF-OCT image (A) as compared to the corresponding histology 
image (B). This is due to a slightly different imaging depth. Scale bars represent 100 µm (A-B), 150 µm (C-D), 
250 μm (K-L, and M-N), and 1 mm (E-F, G-H, and I-J). Insets show a characteristic primordial follicle (A-B) at 
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Figure 2. Example inverse FF-OCT images and corresponding histology images of ovarian metastases 
originating from a primary invasive ductal breast carcinoma
A sagittal view is shown in panel A, and panels B-E show magnified views of the micrometastases (indicated 

















Figure 3. Example inverse FF-OCT images (left column) and corresponding histology images (right 
column) of ovarian metastases
An ovary containing a solitary metastasis originating from a primary invasive breast carcinoma is shown 
in panels A and B (indicated by arrows). An ovary in which disseminated breast tumor cells are dispersed 
throughout the ovary is shown in panels C and D. Micrometastases originating from a primary endometrial 
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Viability of ovarian tissue measured using a glucose uptake assay
Next, we examined whether performing FF-OCT imaging on fresh cortical ovarian tissue affects 
tissue viability. Table 1 shows the mean glucose consumption per mg ovarian tissue per day over 
a 4-day culture period of the fresh cortical ovarian tissues that were imaged using FF-OCT for 
0, 3, 10, 60, and 180 minutes. All values were adjusted for the number of ovaries used, and 
none reached statistical significance. Thus, cortical ovarian tissue remained viable — at least 
with respect to glucose uptake — up to three hours of FF-OCT imaging. No glucose uptake was 
measured in the cortical ovarian biopsies in which cell death was induced.
Table 1. Viability of cortical ovarian tissue after different FF-OCT exposure times
Glucose uptake (mmol/mg tissue/day)
Mean 95% CIa
FF-OCT imaging time
0 minutes 50.52 42.66 - 58.38
3 minutes 46.49 38.63 - 54.35
10 minutes 44.25 36.40 - 52.11
60 minutes 40.32 32.46 - 48.18
180 minutes 46.25 38.39 - 54.11
 
a CI; confidence interval
The mean glucose uptake over a 4-day culture period was determined in triplicate, as described in the material 
and methods section. All values were adjusted for the various ovaries, using a multivariate linear regression 
model, resulting in a standard error of the mean of 4.01.
Viability of preantral ovarian follicles measured using neutral red staining
We also examined the effect of different FF-OCT exposure times on the viability of preantral 
follicles in fresh cortical ovarian tissue fragments using neutral red staining. The percentage of 
viable preantral follicles in the samples that were not subjected to FF-OCT imaging was 86% (95% 
CI 0.81-0.92; Table 2). Although some variation was observed, this viability did not significantly 
decrease following FF-OCT imaging for up to 60 minutes. Cortical ovarian tissue fragments 
that were exposed to FF-OCT for 180 minutes had a significantly lower percentage (55%) of 
viable preantral follicles. As a negative control, no viable preantral follicles were observed in the 
cortical ovarian tissues in which cell death was induced. Figure 4 shows representative examples 
of preantral follicles in fresh cortical ovarian tissues that were not exposed to FF-OCT imaging 
(Figure 4A), preantral follicles that were subjected to FF-OCT imaging for 10 minutes (maximum 
time required to image a cortical ovarian fragment; Figure 4B) and preantral follicles that were 
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Table 2. Viability of preantral follicles after different FF-OCT exposure times
Total number of 
follicles observed




0 minutes 145 125 0.86 0.81 - 0.92
3 minutes 208 183 0.88 0.84 - 0.92
10 minutes 193 189 0.98 0.96 - 1.00
60 minutes 195 185 0.95 0.92 - 0.98
180 minutes 179 99 0.55 0.48 - 0.63
a CI; confidence interval
The proportion of viable preantral follicles was determined by a neutral red staining. Results are based on 
three different cortical ovarian fragments per condition.
Figure 4. Viability of preantral follicles before and after FF-OCT imaging
Representative images of preantral follicles in fresh cortical ovarian tissues that were not exposed to FF-OCT 
imaging are shown in panel A. Preantral follicles in cortical ovarian tissues that were subjected to FF-OCT 
imaging for 10 minutes are shown in panel B. Preantral follicles in cortical ovarian tissues that were subjected 
to FF-OCT imaging for 180 minutes are shown in panel C. The white and black arrows indicate red-colored 
(i.e., viable) and uncolored (i.e., non-viable) follicles, respectively. Scale bars represent 100 μm. 
Discussion
In this proof-of-concept study, we investigated whether FF-OCT can be used to detect metastases 
in ovarian tissue prior to autotransplantation, thereby reducing the risk of reintroducing ovarian 
tissue that might contain metastases. We found that FF-OCT can be used to visualize both 
normal structures and metastases — including micrometastases — in ovarian tissues derived from 
premenopausal women. These findings are particularly relevant from a clinical perspective, given 
that the pathologist must distinguish between benign and malignant lesions based solely on 
tomographic images. Routine pathology methods such as histology and immunohistochemistry 
cannot be used in this context, as these methods render the cortical ovarian tissue unsuitable for 
autotransplantation. Importantly, our results may serve to help pathologists use FF-OCT as a novel 
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In our study, we used deparaffinized FFPE tissue samples, as fresh ovarian tissues were not 
readily available for research purposes and ovarian metastases are relatively rarely encountered. 
However, we found no difference with respect to visual assessment of normal ovarian structures 
between the deparaffinized ovarian tissue samples and the fresh ovarian tissues that were used 
for measuring viability. Our finding is supported by a study of Wilson et al. in which the optical 
features of various non-paraffinized and deparaffinized tissues were compared and no substantial 
differences were found.25 
Because of the relatively few number of ovarian tissue samples that contained micrometastases, 
we were unable to perform a blinded analysis in which two pathologists independently assessed 
the FF-OCT images without having access to the original H&E-stained tissue sections. Such an 
analysis would require a ‘training set’ in order to familiarize the pathologists with non-neoplastic 
and neoplastic ovarian tissues on FF-OCT, followed by a ‘test set’ for which the sensitivity and 
specificity of FF-OCT imaging could be determined.14-15 Although this type of analysis was 
beyond the scope of this proof-of-concept study, it should be performed in future studies in 
order to confirm whether FF-OCT is a suitable diagnostic instrument for use in ovarian tissue. 
The maximum depth of FF-OCT imaging that provided high-resolution images in the cortical 
ovarian strips was approximately 100 μm, which is considerably lower than the imaging depth 
of up to 500 μm reported for other tissues.10 This difference is due primarily to the large-scale 
extracellular matrix network in the ovarian cortex,26-27 which greatly reduces tissue penetration.28 
Nevertheless, imaging depth could be increased somewhat by imaging the cortical ovarian tissue 
fragments from both sides, thereby effectively doubling the amount of tissue that can be imaged. 
Moreover, rapid advances in the field of optical imaging will likely enable clinicians to use this 
non-invasive approach to visualize even deeper structures in the near future. 
Interestingly, previous studies that used conventional OCT to examine ovaries achieved an 
imaging depth of up to 2 mm.29-30 However, the imaging resolution of conventional OCT is 
considerably lower than FF-OCT.31 For our purposes, achieving ultra-high resolution is crucial, 
as patients with clinically diagnosed early-stage cancer who are eligible for cryopreservation of 
ovarian tissue can potentially have occult micrometastases in their ovarian tissues.32-34 Importantly, 
FF-OCT imaging provides images with a resolution of approximately 1 μm.31 In addition to the 
detection of occult ovarian involvement, this high-resolution imaging modality provides the 
opportunity to visually assess the density of primordial follicles in the ovarian autografts, which is 
highly relevant, given that successfully restoring ovarian activity depends critically on the number 
of primordial follicles present in the ovarian autograft.3 Thus, FF-OCT provides the added value of 
selecting the cortical ovarian fragments with the highest potential for restoring fertility. 
Because FF-OCT generates images at a rapid rate,15 this technique is particularly suitable to 
the field of ovarian tissue cryopreservation, where ischemia and oxidative stress during a lengthy 
avascular period are known to cause loss of primordial follicles.35 The average time required to 
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original FF-OCT system, and this time was reduced further to a mere one minute with the newly 
developed FF-OCT system. During these brief periods, the viability of both the ovarian tissue and 
the preantral follicles remained high. Even performing FF-OCT imaging for 180 and 60 minutes 
did not significantly reduce the viability of ovarian tissues and preantral follicles, respectively. 
These data support the notion that short-term FF-OCT imaging has little effect on either ovarian 
tissues or preantral follicles. Nevertheless, given that the most meaningful outcome in the field of 
fertility preservation is ultimately a successful pregnancy, future research will focus on evaluating 
pregnancy rates following exposure to FF-OCT. 
With respect to using FF-OCT as a non-invasive means to detect metastases in the actual 
ovarian autografts, cortical ovarian strips can be imaged immediately following oophorectomy 
(see the proposed workflow diagram in Supplementary Figure 1). If the pathologist observes 
lesions that raise a suspicion of metastases, these fragments could then be analyzed further 
using histological examination and/or PCR analysis. If these further tests confirm the presence 
of metastatic tissue in the ovarian fragments, no autotransplantation will be performed. On the 
other hand, if the histological results are negative (i.e., a false positive result on FF-OCT), the 
remaining ovarian fragments—particularly those fragments that appeared normal on FF-OCT 
imaging—can still be transplanted. Moreover, as discussed above, the pathologist can also select 
the tissue fragments with the highest density of follicles, thereby maximizing the likelihood of 
restoring the patient’s ovarian function. Importantly, FF-OCT imaging should be performed under 
sterile conditions in order to prevent bacterial contamination. 
In conclusion, FF-OCT imaging is a promising new non-invasive method for rapidly detecting 
ovarian metastases in ovarian fragments prior to autotransplantation in patients whose ovarian 
function has been lost. Moreover, this method facilitates the selection of cortical ovarian tissues 
with the highest density of primordial follicles, significantly increasing the likelihood of restoring 
ovarian function. Although it is not yet possible to detect all ovarian metastases and/or follicles in 
the cortical ovarian fragments due to a limited tissue penetration depth, FF-OCT provides a large 
improvement over the current tumor detection methods as it is the only approach now available 
by which the actual ovarian autografts, used for transplantation, can be examined.
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Supplementary Figure S1. Proposed clinical workflow for screening cortical ovarian strips prior to 
autotransplantation in order to minimize the likelihood of reintroducing tumor cells and maximize 
the likelihood of restoring ovarian function
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Over the past years, cryopreservation and subsequent autotransplantation of ovarian tissue 
has become more prominent in the field of fertility preservation. Ever since the first successful 
autotransplantation,1 much research has been performed on establishing patient selection 
criteria,2 the efficiency of different freezing and transplantation techniques,3-7 and the safety 
of this procedure in cancer patients.8-10 Although a tremendous amount of knowledge has 
been gained from these studies, the safety of this procedure has not yet been fully elucidated. 
Through the studies in this thesis, we aimed to further determine the safety of ovarian tissue 
autotransplantation. Besides, we made an initial step toward the development of novel methods 
for the detection of ovarian metastases such as near-infrared fluorescence imaging and full-
field optical coherence tomography, which may help overcome the limitations associated with 
the current tumor detection methods. Central in this thesis were studies on ovarian metastases 
derived from primary invasive breast cancer, as the majority of patients who undergo ovarian 
tissue cryopreservation are diagnosed with this condition and relatively much ovarian tissue is 
available due to prophylactic and/or therapeutic oophorectomies. 
The likelihood of developing ovarian metastases
Recent reviews of the literature on the risk of reintroducing malignancy following ovarian tissue 
autotransplantation revealed that leukemia and lymphoma have the highest and lowest risk of 
developing ovarian metastases, respectively.8,9 With respect to breast cancer, ovarian metastases 
were described to occur in 13-47% of patients.9,11 Yet, the vast majority of published data were 
based on autopsies as well as therapeutic oophorectomies and therefore likely restricted to 
patients with advanced stage disease. In the study described in chapter 2, a prevalence rate of 
2.4% of ovarian metastases was found among young breast cancer patients who underwent an 
oophorectomy for prophylactic or therapeutic reasons. Despite the fact that the prevalence of 
ovarian metastases in patients whose ovaries remained in situ could not be determined, these 
findings showed that the likelihood of encountering secondary ovarian involvement among 
young breast cancer patients is relatively low. 
The majority of the ovarian metastases described in chapter 2 were clinically indolent and 
diagnosed following prophylactic or therapeutic oophorectomy after a median time interval of 
47 months since the diagnosis of breast cancer. Although some time has elapsed before overt 
metastases were formed, breast cancer cells may have spread to the ovaries early in the course 
of the disease. It is thought that tumor cells that are endowed with metastatic capacity soon 
escape from the primary tumor and transmit to secondary target organs, where they enter a 
quiescent state for an indefinite period.12,13 Whether these cells subsequently cease dormancy 
and progress into metastatic lesions depends on molecular interactions between cancer cells 
and the microenvironment of the secondary organ.12,14 These interactions rely on crosstalks with 
different host cell types such as endothelial cells, immune cells, fibroblasts and/or other stromal 
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This implies that, although it remains uncertain whether disseminated tumor cells eventuate in 
overt ovarian metastases, tumor cells might be present at the time of ovarian tissue harvesting.
Risk factors for the development of ovarian metastases
According to the current selection criteria for ovarian tissue autotransplantation, patients should 
have a realistic chance of survival.2,16 These criteria seem justified, as they may reduce the chance 
that a patient dies several months after the birth of her child.17 Yet, these selection criteria do not 
specifically include criteria that may reduce the risk of developing ovarian metastases. In chapter 
2, we therefore aimed to identify risk factors for the development of ovarian metastases in young 
breast cancer patients in order to more comprehensively define selection criteria for ovarian tissue 
cryopreservation in these patients. In this study, a strikingly high percentage of clinically evident 
metastatic disease at the time of oophorectomy was observed among the 57 cases of whom 
clinical data were available; nine patients (16%) had distant metastases outside the ovary at the 
time of breast cancer diagnosis. These results are in line with a previous study of Gagnon and Têtu 
who found that 12 out of 39 breast cancer patients who were diagnosed with ovarian metastases 
(20%), had stage IV disease at the time of breast cancer diagnosis.18 Unfortunately, the presence 
of distant metastases as an independent risk factor for the development of ovarian metastases 
could not be confirmed in our study, as this factor could not be included in the multivariate logistic 
regression models due to empty categories in the matched control group. On the other hand, 
several risk factors for the development of ovarian metastases were identified in our study. We 
showed that the risk of ovarian metastases increased with the time elapsed since breast cancer 
diagnosis. Furthermore, a statistically significant association between the development of ovarian 
metastases and tumor stage was observed in the multivariate logistic regression analyses. Hence, 
particularly young breast cancer patients with tumors > 5 cm in diameter and/or inflammatory 
breast cancer are at risk of developing ovarian metastases. 
The morphological features of ovarian metastases and the accuracy of the current tumor 
detection approach
In the study described in chapter 4, we found that 71% of the ovarian metastases included 
in the study manifested as a solitary metastasis or multiple distinct nodules separated by 
uninvolved ovarian tissue. Though, in patients who undergo ovarian tissue cryopreservation, an 
oophorectomy is much earlier performed than in the patients included in the study described 
in chapter 4. It is presumable that in this former group of patients, tumor cells manifest as 
micrometastases and/or single cells. Hence, the chance that disseminated tumor cells will be 
overlooked in the ovarian tissues from patients undergoing ovarian tissue cryopreservation will 
likely be even greater using the current tumor detection approach. The only option now available 
to corroborate this hypothesis would be to scrutinize cortical ovarian fragments from deceased 
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a study is limited by the fact that relatively little cortical ovarian tissue from deceased cancer 
patients is available. Besides, if such studies reveal that ovarian metastases appear as single 
tumor cells, it will remain difficult to interpret these results in terms of clinical significance. After 
all, what number of tumor cells within an ovarian autograft is needed to cause cancer relapse 
following ovarian tissue autotransplantation, remains to be questioned. A study conducted by 
Soares et al. showed that xenografting one hundred leukemic cells that were embedded in a 
fibrin matrix appeared to be insufficient to induce leukemia in immunodeficient mice after 20 
weeks.19 Nevertheless, conclusive evidence could not be provided, as cancer cells may outgrow 
differently in humans than in mice.20
With respect to the localization of metastases in the ovary, 70% of the ovarian metastases 
were localized in both the cortex and medulla. In addition, 19% seemed to be confined to 
the cortex. However, because we did not sequentially cut the entire ovary, it is possible that 
tumor cells elsewhere in the medulla may have been overlooked. It would be reasonable that 
disseminated tumor cells, once they have seeded to the ovary, spread from the hilum to the 
medulla and ultimately disperse in the cortex where they become trapped in the capillary bed. 
According to the ‘seed and soil theory’, tumor cells can only grow if they encounter a congenial 
microenvironment.21 Factors that may possibly contribute to the development of metastases in 
the ovarian cortex are for instance the high amount of fibroblasts and the densely packed collagen 
bundles that make up the extracellular matrix in the ovary.13,22,23 Furthermore, it is plausible that 
hormonal circumstances play a prominent role herein, since breast cancer metastases are more 
frequently found in ovaries from premenopausal women.24 
Implications of our findings for routine patient care
What implications do our findings have for routine patient care? In case of ovarian tissue 
autotransplantation, the risk of reintroducing malignant cells needs to be discussed during 
counselling. Breast cancer patients should be informed about the fact that ovarian metastases 
occur in 2.4% of patients diagnosed with breast cancer. Based on the results from our risk factor 
analyses as described in chapter 2, we would discourage ovarian tissue autotransplantation in 
patients diagnosed with tumors > 5 cm and/or inflammatory breast cancer. Besides, since the 
time passed between the diagnosis of breast cancer and oophorectomy seems to play a role in 
the development of ovarian metastases, we recommend to perform an oophorectomy soon after 
the diagnosis of breast cancer and subsequently transplant the cortical ovarian fragments back 
to the remaining ovary. This approach provides the opportunity to completely remove the ovarian 
autografts at a later time, thereby minimizing the risk of developing ovarian metastases. Lastly, 
patients must be told that the current tumor detection approach presumably provides a false 
sense of security. Hence, as long as there is no accurate alternative to the current tumor detection 
approach, the desire to conceive and the likelihood of reimplanting malignant cells should be 
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Non-invasive tumor detection methods
It stands to reason that it would be far better to develop a tumor detection approach by which 
the presence of disseminated tumor cells in the ovarian autografts can be excluded with certainty. 
In this thesis, we focused on two different optical imaging techniques that could possibly be used 
for the detection of ovarian metastases without affecting the ovarian tissue viability, namely near-
infrared fluorescence imaging and full-field optical coherence tomography.
Near-infrared fluorescence imaging 
Near-infrared fluorescence (NIRF) imaging has the potential to revolutionize cancer surgery, as it 
has been proven to provide significant guidance in distinguishing malignant from healthy tissues 
as well as recognizing vital structures.26 A NIRF probe consists of a fluorophore that emits light 
in the near-infrared spectrum (λ = 700-900 nm) conjugated to an antibody or peptide with high 
affinity for a protein marker that is specifically expressed at the cell surface of tumor cells.27,28 In 
the study described in chapter 4, we tested a panel of cell-surface markers in primary invasive 
breast tumors and their corresponding ovarian metastases in order to examine whether primary 
invasive breast tumor tissue can be used to predict which target would be most suitable for the 
detection of the corresponding ovarian metastases by NIRF imaging. Interestingly, no correlation 
could be substantiated between the expression of the markers in the invasive breast tumors 
and their corresponding ovarian metastases. One explanation for this discrepancy could be 
that primary tumors deploy genetic and/or epigenetic alterations in order to successfully spawn 
metastases in distant organs.15 Moreover, once these disseminated tumor cells have invaded 
a secondary target organ, they utilize several signal transduction pathways in order to survive 
in the foreign tissue microenvironment and foster metastatic colonization. As a result of these 
complex mechanisms, metastases may display a different phenotype than their primary tumor. 
Furthermore, this observation could be explained by the molecular and cellular heterogeneity of 
breast cancer.29 
To ensure that an optimal tumor-to-background ratio can be achieved in the cortical ovarian 
fragments, the expression of the investigated markers was examined in ten normal ovaries from 
premenopausal women in chapter 3. Ovaries from women with a BRCA gene mutation or an 
unknown mutation status were excluded, as they could harbor primary ovarian carcinoma cells 
that express the markers investigated in this study and therefore potentially lead to false-positive 
results. Unfortunately, all markers (except CEA and uPAR) were expressed on epithelial cells in 
inclusion cysts. Consequently, administration of NIRF probes against these markers will not only 
illuminate disseminated breast tumor cells in the ovaries, but also inclusion cysts. One solution 
to this problem would be to seek markers that are exclusively expressed at the cell surface of 
these inclusion cysts. Antibodies or peptides against these markers could then be conjugated 
to a fluorophore with an emission wavelength beyond the NIR spectral range, making a clear 
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inclusion cysts are also abundantly present at the cell-surface of breast tumor cells,30 this hurdle 
will not be remedied by this approach. Another possibility would be to use an additional imaging 
technique by which the distinct morphological features of these structures can be visualized. Such 
a technique might be for instance full-field optical coherence tomography. 
Full-field optical coherence tomography 
Full-field optical coherence tomography (FF-OCT) is a new imaging modality that can be used to 
generate high-resolution histology-like images within a short period of time.31 A great advantage 
of this technique is that there is no need to fixate, freeze, or stain the tissue. In chapter 5, we 
investigated whether FF-OCT can be used to visualize metastases as well as normal structures 
in human ovarian tissue. In contrast to the study described in chapter 3 in which BRCA gene 
mutation carriers were excluded, normal ovaries were obtained from premenopausal women 
who underwent prophylactic bilateral oophorectomy because of the presence of a BRCA gene 
mutation. Although the absence of primary ovarian carcinoma cells could not be fully warranted, 
the chance that occult tumor cells would be found was on closer reflection deemed almost nil, as 
the tubal fimbria were free of malignancy in all cases.32
In this study, we found that the maximum tissue depth at which high-resolution could be 
retained for the detection of ovarian metastases and normal ovarian structures was limited to 
approximately 100 μm, whereas previous studies have shown tissue imaging depths up to 500 μm 
in other tissues.31 The reason that we found a much lower tissue penetration depth presumably 
lies in the large-scale extracellular network in the ovarian cortex.22,33 Yet, this limitation could 
partially be solved by imaging the cortical ovarian fragments from both sides, thereby doubling 
the amount of tissue that can be imaged. Reducing ovarian graft thickness to further circumvent 
this limitation is not an option, as it has shown to result in follicle activation and subsequent 
depletion of the primordial follicle pool.34 Nevertheless, although the limited penetration depth 
does not yet allow visualization of all ovarian metastases and/or follicles in the cortical ovarian 
fragments, FF-OCT is the only approach now available that is capable of examining the actual 
ovarian autografts without compromising the ovarian tissue and follicle viability. 
Feasibility of NIRF imaging and FF-OCT for the detection of ovarian metastases and 
future perspectives
To determine whether optical imaging is feasible for routine use in fertility preservation, a number 
of steps have yet to be taken. Preclinical studies should be designed that provide sufficient 
evidence to support or reject the notion that NIRF imaging and FF-OCT are safe and efficacious 
for use in human ovarian tissues. Although a combination of NIRF probes would ultimately be 
indispensable to detect all disseminated breast tumor cells in ovarian tissue, these studies should 
initially be tailored to one tumor-targeted fluorescent probe to establish proof of concept. As 
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metastases (chapter 4) and the majority of breast cancer patients are diagnosed with infiltrating 
ductal carcinoma,35 it would be beneficial to develop a clinically applicable probe that is specifically 
directed to E-cadherin. To this end, antibodies or peptides against E-cadherin could be conjugated 
to a fluorophore that is currently available for clinical use, for instance IRDye 800CW (LI-COR 
Biosciences, Lincoln, NE) or ZW800-1 (The FLARE foundation, Wayland, MA). Alternatively, 
clinically approved antibodies like trastuzumab (Herceptin; Genentech, San Francisco, CA) could 
be labelled with IRDye 800CW to detect tumor cells that express Her2/neu.36,37 This probe might 
be particularly suitable for the detection of ductal and lobular breast tumor cells in the ovarian 
tissues, as described in chapter 4. Such antibodies have the further advantage that their safety 
and toxicity profiles have already been broadly investigated and approved for clinical application. 
After verification of the binding capacity of the NIRF-labelled antibodies using a cell-based plate 
assay, the probes can be used for preclinical in vivo imaging studies to test their suitability for the 
field of ovarian tissue autotransplantation.38 In these studies, severe combined immunodeficient 
(SCID) mice or rats can be used that bear orthotopically implanted ‘metastatic’ ovarian tumors 
that are induced by injection of a breast cancer cell line. This breast cancer cell line should 
obviously be positive for the markers to which the probe is directed and preferably express green 
fluorescent protein (GFP), which could serve as a positive control during the imaging process.39 
Bochner et al. reported in vivo imaging of GFP-expressing human ovarian carcinoma cells that 
were xenotransplanted in the ovaries of nude mice.40 After mounting an imaging window on the 
right dorsolateral side of the mouse, and subsequent exteriorization of the murine ovary from 
the abdominal cavity, tumor cell migration could be tracked using a multiphoton microscope. 
For our purpose, NIRF-labelled antibodies could be administered via tail vein injection. Following 
this, binding of these NIRF-labelled antibodies to proteins that are present at the cell-surface of 
the GFP-expressing breast tumor cells in the murine ovary can be imaged using a multiphoton 
microscope. An alternative to multiphoton microscopy might be photoacoustic imaging (PAI).41 
This emerging new imaging technique detects acoustic signals that are indirectly generated by 
photon absorption following tissue illumination, and possibly allows for deeper tissue imaging. 
For optimal differentiation between the antigen-expressing tumor cells and the surrounding 
stromal cells, a sufficient tumor-to-background ratio is of utmost importance. Within this context, 
rapid elimination of fluorescent agents from the circulation by either the kidney or liver is crucial. 
To accelerate this clearance process, smaller targeting molecules such as F(ab’)2 and Fab fragments 
can be used.42 These fragments retain the specificity and affinity of their parental antibody. 
Furthermore, they are usually less immunogenic due to lack of the Fc domain.43 
For the objective to use NIRF imaging to detect malignant cells in cortical ovarian tissue prior 
to cryopreservation, a tumor-specific probe that has been approved for clinical use could be 
intravenously administered to the patient before oophorectomy. After oophorectomy, the ovary 
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With respect to FF-OCT, it is expected that this imaging technique can be relatively quickly 
implemented into daily clinical practice. Additional studies are needed to determine whether 
FF-OCT is a suitable diagnostic instrument for use in ovarian tissue. This could be established by 
performing a blinded analysis in which two pathologists independently assess FF-OCT images 
of human ovarian tissues without having access to the H&E-stained tissue sections of these 
samples. Cortical ovarian tissues from deceased cancer patients can be used to estimate the 
tumor detection limit. Furthermore, research should focus on the ability of having offspring 
following autotransplantation of ovarian autografts that have been exposed to FF-OCT imaging. 
To this end, cortical ovarian fragments, whether or not exposed to FF-OCT imaging, can be 
xenotransplanted to bilaterally oophorectomized SCID mice to assess follicle development, as 
previously described by Lotz et al.46 Furthermore, murine ovarian tissue could be subjected to FF-
OCT imaging and transplanted back to mice that previously underwent bilateral oophorectomy. 
Mature oocytes could then be harvested from the excised ovarian tissue, fertilized in vitro and 
transferred to surrogate mouse mothers to generate full-term offspring.47 If these studies yield 
successful results, FF-OCT imaging could shortly thereafter be used as a non-invasive means to 
detect metastases in the ovarian autografts and ultimately replace the current tumor detection 
methods. 
Other strategies to mitigate the risk of reintroducing cancer cells following ovarian 
tissue autotransplantation
In addition to optical imaging, other strategies are being developed that may potentially mitigate 
the risk of reintroducing malignant cells. These strategies can basically be subdivided into three 
categories. Firstly, strategies that aim to attenuate the harmful effects of the gonadotoxic 
treatments on the ovaries. Current research focuses on reducing the uptake of chemotherapeutic 
agents in non-targeting tissues by nano-encapsulation of the drugs,48,49 and inhibiting the 
apoptotic effects of chemotherapy on actively growing ovarian follicles by co-treatment with 
either sphingosine-1-phosphate (S1P),50 or trichloro(dioxoethylene-O,O’) tellurate (AS101).51 If 
these approaches turn out to be effective, fertility preservation may become even unnecessary. 
Secondly, strategies that are designed to eradicate tumor cells from the ovarian autografts, for 
instance by tumor cell purging.52,53 Tumor cell purging aims to eliminate malignant cells from 
the cortical ovarian fragments, while leaving the ovarian reproductive function intact. Hence, 
as is the case with NIRF imaging and FF-OCT, purging of tumor cells has the intention to allow 
for ovarian function recovery upon ovarian tissue autotransplantation. Thirdly, strategies that 
focus on isolation of oocytes rather than eradication of tumor cells from ovarian tissue, for 
example in vitro maturation of immature oocytes.54-56 Although in vitro maturation of human 
primordial follicles is still in its infancy,54 two live births have been reported following in vitro 
maturation of prophase I oocytes that were aspirated from extracorporeal human ovarian 
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approach to obtain mature oocytes. Xenotransplantation of ovarian tissue from a 6-year old girl 
diagnosed with nephroblastoma to a bilaterally oophorectomized SCID mouse recently resulted 
in the spontaneous formation of an antral follicle, which subsequently matured in vitro to a 
metaphase II oocyte.46,57 Furthermore, it is possible to transplant isolated preantral follicles in a 
fibrin scaffold, thereby creating a so-called artificial ovary.58,59 In mice, this approach has recently 
led to viable offspring.47 Elaborating on this, pluripotent cell-derived stem cells may constitute 
a success for fertility restoration in the long term.60 Primordial germ cell-like cells derived from 
female embryonic stem cells recently produced meiotically competent oocytes in mice. These 
oocytes were subsequently matured in vitro, fertilized, and transferred to foster mouse mothers, 
eventually resulting in healthy descendants. Of note, although these latter strategies are very 
promising, they do not allow for ovarian function recovery.
Final conclusion
Over the past few years, major advances have occurred in both understanding the risk of 
reintroducing malignant cells by ovarian tissue autotransplantation and the development of novel 
approaches that all aim to reduce this risk to a negligible level. The rate of progress is certainly 
laudable, but serious challenges remain ahead before the current concerns can be permanently 
dispelled. Although compelling evidence is still lacking, our results indicate that the current tumor 
detection approach provides insufficient information regarding the presence of malignant cells 
in the actual ovarian autografts. With this in mind, and the fact that the vast majority of cancer-
related deaths are due to metastatic tumor growth,61 it is of utmost importance to continue 
scientific research in this field. Optical imaging needs to form part of this research, as it holds 
considerable promise for application in the field of fertility preservation. In contrast to other risk-
reducing approaches that primarily aim at ensuring the ability of having genetic offspring, for 
instance in vitro maturation of immature oocytes, NIRF imaging and FF-OCT have the potential 
to preserve the ability of ovarian function recovery by ovarian tissue autotransplantation. Besides, 
due to their non-invasiveness, it may be possible to examine ovarian tissues by both NIRF imaging 
and FF-OCT, resulting in even higher sensitivity and specificity rates. Lastly, while the focus of this 
thesis was mainly on ovarian metastases derived from invasive breast cancer, both methods can 
be converted to other malignancies in which cryopreservation of ovarian tissue is performed. 
As a result, patients may also become eligible in whom ovarian tissue autotransplantation is 
currently explicitly discouraged because of the high risk of transferring malignant cells upon 
autotransplantation. Hence, optical imaging may ultimately extend the range of people to whom 
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The safety of ovarian tissue autotransplantation in cancer patients cannot yet be ascertained, as 
the actual ovarian autografts cannot be examined for the presence of ovarian metastases. This is 
due to the fact that the current tumor detection methods undermine the ovarian tissue viability. 
The studies described in this thesis focused on determining the risk of reintroducing malignant 
tumor cells following ovarian tissue autotransplantation using the current tumor detection 
approach, and novel detection methods by which metastatic disease can potentially be detected 
in the cortical ovarian fragments that are actually transplanted.
In chapter 1, a detailed review of the literature is given on the morphology and localization of 
ovarian metastases derived from primary neoplasms in which cryopreservation of ovarian tissue 
is performed. Based on this literature review, we found indications that metastases in the ovarian 
cortex can be exclusively present in a distinct area. These indications implied that the absence of 
disseminated tumor cells cannot be guaranteed in the actual ovarian autografts when the cortical 
ovarian fragments that were examined, do not contain metastatic tumor cells. The current tumor 
detection approach might therefore be considered inadequate. 
Since breast cancer is one of the primary indications for ovarian tissue cryopreservation, 
we further focused on ovarian metastases derived from invasive breast cancer in this thesis. 
Chapter 2 describes a nationwide retrospective cohort study in which the prevalence of ovarian 
metastases was explored among all patients with primary invasive breast cancer at age < 41 years 
in the period 2000-2010 in the Netherlands who subsequently underwent an oophorectomy. 
In this cohort, 63 out of 2642 patients (2.4%) had histologically confirmed ovarian metastases. 
Between these 63 cases and the 2535 controls without ovarian metastases in this population, 
a noticeable difference was found in the time interval between the diagnosis of breast cancer 
and oophorectomy, 47.0 and 32.0 months, respectively (p = 0.002). Based on these findings, 
we concluded that the risk of developing ovarian metastases may be reduced by performing an 
oophorectomy promptly after the diagnosis of breast cancer. Besides, grafting the cortical ovarian 
fragments to the ovary that remained in situ instead of, for instance, a peritoneal window may 
help to alleviate the risk of developing ovarian metastases, as it enables the complete extirpation 
of the cortical ovarian autografts at a later time. Multivariate logistic regression analyses 
performed in a case-control population that was matched on the time interval between breast 
cancer diagnosis and oophorectomy, showed that tumor stage was significantly associated with 
the development of ovarian metastases (p = 0.024). Hence, we should be careful with ovarian 
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Near-infrared fluorescence (NIRF) imaging can be used to make a distinction between malignant 
and healthy tissues without modifying the examined tissues and can therefore potentially surmount 
the disadvantages of the current tumor detection methods. The first step towards developing 
tumor-specific NIRF imaging as a novel method for the detection of ovarian metastases is the 
identification of protein markers that are present at the cell surface of tumor cells, but absent on 
cells that compose the normal ovarian cortex. In chapter 3, we examined a panel of eight cell-
surface markers in ten normal ovaries from premenopausal women by immunohistochemistry. 
We found that none of the ten ovaries were positive for any of the markers tested. However, all 
markers (except CEA and uPAR) were found on epithelial cells of inclusion cysts. Additionally, we 
studied the same panel in 24 primary invasive breast tumors from patients who were potentially 
eligible for ovarian tissue cryopreservation following the inclusion criteria of the Dutch Network of 
Fertility Preservation. We concluded that particularly E-cadherin could be suitable as a target for 
tumor-specific NIRF imaging, as E-cadherin was expressed by 94% of invasive breast tumor cells 
in these 24 breast tumors. However, our analysis was limited to a cohort that mainly consisted 
of ductal breast cancers. Moreover, these findings did not necessarily infer that metastatic breast 
tumor cells express these markers to the same extent at their cell surface. 
In chapter 4, we therefore investigated the expression of the above-mentioned panel of 
cell-surface proteins in ovarian metastases from the previously described cohort of patients who 
were diagnosed with primary invasive breast cancer at age < 41 years in the period 2000-2010 
in the Netherlands. The markers uPAR and FR-α were excluded from further analyses, as they 
were barely expressed by the primary invasive breast tumors tested in chapter 3. With respect to 
ovarian metastases from the ductolobular subtype, EMA resulted to be the most suitable marker, 
as it was present on the cell membrane of 99% of disseminated ductolobular breast tumor cells 
in the seven ovaries studied. An immunofluorescent triple staining revealed that in ductal ovarian 
metastases, a combination of the markers E-cadherin, EMA and Her2/neu led to the detection 
of 100% of metastatic breast tumor cells in 53 out of 58 ovarian metastases. By combining 
EMA, Her2/neu and EpCAM, 100% tumor cell detection could be reached in 7 out of 10 lobular 
ovarian metastases. In the remaining five ductal and three lobular ovarian metastases, the mean 
percentage of metastatic cells that could not be detected was 5% (no range) and 25% (range 
10-40), respectively. These data showed that the diagnosis of the histological subtype could aid 
in selecting the most pertinent combination of markers for the detection of ovarian metastases 
by tumor-specific NIRF imaging. This is clinically relevant, as we found that the expression of the 
cell-surface markers in primary invasive breast cancer tissues cannot be used to predict the most 
suitable target for the detection of ovarian metastases in an individual patient. 
In addition to the expression of cell-surface markers, chapter 4 was also designed to 
strengthen the findings from our review of the literature on the localization and morphology 
of ovarian metastases, as described in chapter 1. To this end, we studied the distribution of 
disseminated breast tumor cells within ovarian tissues from breast cancer patients who were 
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metastases consisted of a solitary metastasis or multiple distinct nodules separated by uninvolved 
ovarian tissue. These findings confirm the results of the previously reported studies in the literature 
and suggest that in these ovarian tissues disseminated breast tumor cells might not have been 
detected if the current tumor detection approach was applied. Yet, in the patients included in our 
study, there was a median time interval of 42 months between the diagnosis of breast cancer and 
oophorectomy. By contrast, in patients who undergo ovarian tissue cryopreservation a unilateral 
oophorectomy is usually performed shortly after cancer diagnosis. It is therefore likely that in 
these latter patients, ovarian metastases manifest as micrometastases or perhaps even single 
cells. Thus, in patients who undergo ovarian tissue cryopreservation, there might be an even 
greater chance that disseminated tumor cells in the ovarian tissues will be missed using the 
current tumor detection approach. Additional research is required to validate this. 
In addition to NIRF imaging, full-field optical coherence tomography (FF-OCT) might be an 
appropriate approach to detect ovarian metastases in a non-invasive manner. FF-OCT is a new 
imaging system by which high-resolution histology-like images can be produced. These images 
can be obtained without the need to fixate, freeze, or stain the tissue. In the study described 
in chapter 5, we investigated whether FF-OCT can be used to visualize metastases as well as 
normal structures in human ovarian tissue. We found that micrometastases measuring up to 
0.9 mm in diameter derived from primary breast cancers and endometrial cancers could be 
clearly distinguished from the surrounding stromal cells up to a tissue imaging depth of 100 μm. 
Furthermore, follicles of all stages of development and inclusion cysts could be identified. Since 
FF-OCT enabled the assessment of the density of primordial follicles, this method can also be used 
to select cortical ovarian fragments that have great potential for restoring fertility. Besides, we 
evaluated whether ovarian tissues and follicles remained viable following FF-OCT imaging. We 
found that short-term exposure to FF-OCT imaging had no significantly different effect on ovarian 
tissues and preantral follicles. Using the original FF-OCT system, it took on average seven minutes 
to image a cortical ovarian fragment measuring 5-10 mm in diameter. With the newly developed 
FF-OCT system, this time was diminished to one minute. We concluded that, although the limited 
imaging depth should certainly be taken into account, FF-OCT is at present the only approach by 
which it is possible to examine the actual ovarian autografts and thus, has significant advantages 
over the current tumor detection methods.
In chapter 6, the general discussion, we concluded that both NIRF imaging and FF-OCT have high 
potential to exclude minimal residual disease in the actual ovarian autografts. Despite the fact 
that the studies described in this thesis were primarily dedicated to ovarian metastases in patients 
diagnosed with breast cancer, it is expected that both optical imaging techniques can similarly be 
used for the detection of ovarian metastases derived from other primary malignancies, making 
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Dankzij verbeterde screeningsmethoden en nieuwe behandeltechnieken is de kans op het over-
leven van kanker de laatste decennia enorm toegenomen. Tot deze nieuwe behandeltechnieken 
behoren onder andere chemotherapie en bestraling. Helaas hebben bestraling op het bekken 
en sommige vormen van chemotherapie een schadelijk effect op de eierstokken en kunnen zij 
leiden tot vroegtijdige uitval van de eierstokfunctie. Hierdoor ontstaan klachten die gerelateerd 
zijn aan een tekort aan oestrogenen, zoals osteoporose (botontkalking), een verhoogd risico op 
hart- en vaatziekten, vasomotorische symptomen (onder andere opvliegers en hartkloppingen) 
en verminderde emotionele gesteldheid. Daarnaast kunnen deze behandelingen resulteren in een 
verminderde vruchtbaarheid of onvruchtbaarheid. Het risico op een verminderde vruchtbaarheid 
en onvruchtbaarheid neemt toe met de leeftijd en is gerelateerd aan het type chemotherapeuticum, 
de dosering en de duur van de behandeling. Al deze gevolgen hebben een negatieve invloed op 
de kwaliteit van leven van jonge vrouwen met kanker. 
Om jonge vrouwen met kanker de nadelige effecten van deze behandelingen te besparen, is 
een aantal vruchtbaarheidssparende behandelingen ontwikkeld. De huidige vruchtbaar-
heidssparende behandelingen zijn het invriezen van embryo’s, eicellen, of eierstokweefsel. 
Het invriezen van embryo’s en het invriezen van eicellen zijn erkende methoden die algemeen 
beschikbaar zijn. Zij kennen echter enkele nadelen. Ten eerste is hormonale stimulatie nodig 
om eicellen te verkrijgen. Dit heeft tot gevolg dat deze methoden noch geschikt zijn voor jonge 
meisjes bij wie de menstruele cyclus nog niet op gang is, noch voor vrouwen die onvoldoende tijd 
hebben om hormonale stimulatie te ondergaan. Ten tweede kan de eierstokfunctie door middel 
van deze methoden niet worden hersteld. Het invriezen van eierstokweefsel biedt mogelijk 
uitkomst.
Invriezen en terugplaatsen van eierstokweefsel
Voor jonge meisjes en vrouwen die direct moeten starten met chemotherapie en/of bestraling 
vanwege een agressieve vorm van kanker is het invriezen van eierstokweefsel de enige optie. 
Bovendien is het de enige vruchtbaarheidssparende behandeling waarmee de eierstokfunctie kan 
worden hersteld. Om in aanmerking te komen voor het invriezen van eierstokweefsel moet aan 
een aantal criteria worden voldaan. Deze criteria zijn onder andere: leeftijd < 35 jaar, een goede 
eierstokreserve, een realistische kans op overleving en een hoog geschat risico op uitval van de 
eierstokfunctie door de oncologische behandeling (> 50%). Overigens zijn deze selectiecriteria 
indicatief. Het invriezen van eierstokweefsel is in het verleden ook uitgevoerd bij vrouwen die iets 
ouder waren dan 35 jaar.
Het eierstokweefsel wordt bij voorkeur ingevroren voordat de behandeling met chemo-
therapie en/of bestraling plaatsvindt. Tijdens een kijkoperatie wordt één van de eierstokken 
verwijderd. Deze eierstok wordt vervolgens naar het laboratorium gebracht. Aldaar wordt de 
eierstok gehalveerd en het merg (de binnenzijde van de eierstok) verwijderd. De overgebleven 
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tot een dikte van 1-2 mm en in fragmenten gesneden van 5-10 mm doorsnede. Vervolgens 
worden de eierstokfragmenten ingevroren en opgeslagen in vloeibare stikstof (-196 °C). Als na 
de behandeling van de patiënte sprake blijkt te zijn van een verminderde eierstokfunctie en de 
patiënte een kinderwens heeft, kunnen de eierstokfragmenten worden ontdooid en worden 
teruggeplaatst in de achtergebleven eierstok en/of het buikvlies (orthotope terugplaatsing), of 
in de buikwand of de onderarm (heterotope terugplaatsing). Herstel van de menstruele cyclus 
na terugplaatsing van eierstokweefsel werd voor het eerst beschreven in 2001, gevolgd door de 
eerste levendgeborene in 2004. Tot op heden zijn wereldwijd meer dan 86 levendgeborenen 
gerapporteerd, deels na spontane conceptie en deels na in vitro fertilisatie (IVF). In Nederland is 
in 2015 de eerste baby geboren na terugplaatsing van eierstokweefsel in het Leids Universitair 
Medisch Centrum (LUMC). Bij 93% van de patiënten treedt na terugplaatsing van het 
eierstokweefsel herstel van de eierstokfunctie op. 
Experimentele aard 
Ondanks deze veelbelovende resultaten wordt terugplaatsing van ontdooid eierstokweefsel 
wereldwijd als experimenteel beschouwd. In ons land heeft Zorginstuut Nederland op 30 november 
2016 een brief geschreven aan mevrouw Schippers, destijds minister van Volksgezondheid, 
Wetenschap en Sport, waarin werd geconcludeerd dat het invriezen en terugplaatsen van 
ovariumweefsel niet voldoet aan de stand van de wetenschap en praktijk. De achterliggende 
reden is tweeledig: in de eerste plaats is de effectiviteit nog onduidelijk, omdat zwanger worden 
ook mogelijk is bij een verminderde vruchtbaarheid en de eierstokfunctie na behandeling met 
chemotherapie soms spontaan herstelt. In de tweede plaats is de veiligheid van deze methode 
nog onvoldoende in kaart gebracht bij bepaalde vormen van kanker die naar de eierstokken 
kunnen uitzaaien. Het gaat hierbij om het risico op het herintroduceren van tumorcellen bij het 
terugplaatsen van eierstokweefsel. 
Bezorgdheid omtrent de veiligheid van terugplaatsing van eierstokweefsel
De veiligheid van het terugplaatsen van eierstokweefsel kan tot op heden niet worden gegaran-
deerd. Dit komt doordat de huidige tumordetectiemethoden (histologie/immunohistochemie, 
PCR-analyse, xenotransplantatie) het eierstokweefsel ongeschikt maken voor terugplaatsing. Om 
die reden wordt op dit moment een beperkt aantal eierstokfragmenten onderzocht dat niet 
wordt teruggeplaatst. Men gaat er dan van uit dat deze onderzochte fragmenten representatief 
zijn voor de gehele eierstok. Of de eierstokfragmenten die wel worden teruggeplaatst 
tumorcellen bevatten, blijft echter onduidelijk. Het zou dus kunnen dat er met het terugplaatsen 
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Evaluatie van de huidige tumordetectieprocedure
Om te bepalen of met het testen van één of twee eierstokfragmenten die niet worden 
teruggeplaatst voorspeld kan worden of tumorcellen afwezig zijn in het eierstokweefsel dat wel 
wordt teruggeplaatst, is het belangrijk om te weten hoe de uitgezaaide tumorcellen zich in het 
eierstokweefsel presenteren en waar zij zich exact bevinden. Dit kan worden geïllustreerd aan de 
hand van de volgende twee voorbeelden. Indien tumorcellen diffuus en homogeen verspreid zijn 
in het eierstokweefsel is het onderzoeken van één of twee eierstokfragmenten voldoende om 
na te gaan of tumorcellen aanwezig zijn in de eierstokfragmenten die worden teruggeplaatst. 
In dat geval kan de huidige tumordetectieprocedure als voldoende nauwkeurig worden 
beschouwd. Daarentegen is de huidige tumordetectieprocedure onbetrouwbaar als uitzaaiingen 
slechts in een beperkt gebied in de schors van de eierstok voorkomen. Dan bestaat de kans 
dat de eierstokfragmenten die onderzocht worden als tumorvrij worden afgegeven, terwijl 
eierstokfragmenten die worden teruggeplaatst uitgezaaide tumorcellen bevatten (‘sampling 
error’).
Non-invasieve tumordetectiemethoden
Een mogelijke benadering om eierstokfragmenten op een veilige manier terug te plaatsen is om 
methoden te ontwikkelen waarmee de aanwezigheid van uitzaaiingen kan worden uitgesloten 
zonder schade te berokkenen aan de vitaliteit van het weefsel. Twee nieuwe technieken zijn 
mogelijk voor dit doeleinde geschikt: nabij-infrarode fluorescente beeldvorming en full-field 
optische coherentietomografie.
Nabij-infrarode fluorescente beeldvorming 
Nabij-infrarode fluorescente (NIRF-)beeldvorming kan worden gebruikt om ‘real time’ onderscheid 
te maken tussen kwaadaardig en goedaardig weefsel zonder het onderzochte weefsel aan te 
tasten. Het voordeel van NIR-licht ten opzichte van zichtbaar licht is dat het licht dieper in het 
weefsel dringt, waardoor het mogelijk is om dieper gelegen structuren te bekijken. Daarnaast 
geeft NIR-licht een lagere autofluorescentie van het normale weefsel waardoor voldoende 
contrast ontstaat. Omdat het humane oog ongevoelig is voor NIR-licht is een camerasysteem 
noodzakelijk om het fluorescente licht te kunnen waarnemen. Dit camerasysteem is uitgerust 
met een lichtbron dat een fluorofoor (een fluorescerende stof) aanstraalt, waarna een fluorescent 
signaal wordt uitgezonden.
Op het gebied van de oncologische chirurgie wordt NIRF-beeldvorming reeds gebruikt 
om met behulp van de fluorescente stoffen indocyanine groen en methyleenblauw weefsels 
te identificeren die moeten worden verwijderd, zoals kwaadaardige tumoren en aangedane 
lymfeklieren, en structuren te herkennen die moeten worden gespaard, zoals urineleiders en 
galwegen. Door de toegenomen vaatvorming en afgenomen lymfeafvloed bij kanker passeren 
deze fluorescente stoffen de haarvaten en hopen zij zich op in het weefsel rondom de tumor, 
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NIRF-gelabelde tumor-specifieke probes kunnen worden gebruikt om tumorcellen nog 
nauwkeuriger op te sporen. Deze tumor-specifieke probes bestaan uit twee componenten: 
antilichamen of peptiden die met hoge affiniteit aan eiwitten op de celmembraan van tumorcellen 
binden en een fluorofoor dat licht uitzendt in het NIRF-spectrum (λ = 700-900 nm). Bij patiënten 
met eierstokkanker blijken uitzaaiingen beter te kunnen worden opgespoord na toediening van 
tumor-specifieke fluorescente probes. Dergelijke tumor-specifieke fluorescente probes zouden 
ook gebruikt kunnen worden om tumorcellen in eierstokweefsel te detecteren.
Om deze techniek te gebruiken voor de detectie van tumorcellen in eierstokfragmenten zou 
preoperatief een tumor-specifieke NIRF-probe intraveneus aan een patiënte met kanker kunnen 
worden toegediend. Nadat de eierstok verwijderd is, kunnen de eierstokfragmenten worden 
verkregen. Omdat deze fragmenten doorgaans een doorsnede hebben van 5-10 mm en een 
dikte van 1-2 mm is een beeldvormingssysteem noodzakelijk waarmee gedetailleerde opnamen 
kunnen worden gemaakt tot een weefseldiepte van ten minste 1 mm. Een multifotonmicroscoop 
lijkt hiervoor zeer geschikt te zijn, aangezien deze ontwikkeld is om een fluorescent signaal in de 
diepte te detecteren. 
Full-field optische coherentietomografie
Full-field optische coherentietomografie (FF-OCT) maakt binnen afzienbare tijd histologie-
achtige afbeeldingen van verse weefselfragmenten tot een weefseldiepte van 500 μm. Het 
beeldvormingssysteem bestaat uit een staande microscoop en een referentiearm in een 
Linnik interferometrische opstelling. FF-OCT detecteert teruggekaatst licht in weefsel. Het te 
onderzoeken weefsel wordt onder het objectief geplaatst. Om te bepalen op welke diepte in 
het weefsel het licht wordt teruggekaatst, wordt het licht zowel naar het weefsel uitgezonden 
als naar een referentiespiegel. Vervolgens wordt het licht gecombineerd ontvangen door een 
detector en wordt een afbeelding gemaakt. FF-OCT kan, in tegenstelling tot de conventionele 
detectiemethoden, worden verricht zonder het weefsel te fixeren, in te vriezen of te kleuren, 
waardoor het weefselbeschadiging kan voorkomen. 
Dit proefschrift
Dit proefschrift richt zich op de veiligheid van het terugplaatsen van ontdooid eierstokweefsel. 
Het doel is om de nauwkeurigheid van de huidige tumordetectieprocedure in kaart te brengen en 
de noodzaak voor een alternatieve methode te bepalen waarmee het mogelijk is om ieder terug 
te plaatsen eierstokfragment te onderzoeken. Daarnaast heeft dit proefschrift tot doel na te 
gaan of NIRF-beeldvorming en FF-OCT mogelijk geschikt zijn als alternatieve detectiemethoden. 
Centraal in dit proefschrift staan studies gewijd aan uitzaaiingen in de eierstokken bij patiënten 
met borstkanker, aangezien de meeste patiënten van wie eierstokweefsel wordt ingevroren met 
borstkanker gediagnosticeerd zijn, en relatief veel eierstokweefsel van deze patiënten beschikbaar 
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of in het kader van de behandeling bij hormoongevoelige borsttumoren worden verwijderd om 
hormonale stimulatie van de borsttumor te voorkomen.
In hoofdstuk 1 wordt een gedetailleerd literatuuroverzicht gegeven van de lokalisatie en de 
vorm van uitzaaiingen in de eierstok. Hierbij lag de focus op uitzaaiingen die afkomstig zijn 
van de verschillende vormen van kanker waarbij eierstokweefsel wordt ingevroren. Deze vormen 
zijn borstkanker, baarmoederhalskanker, baarmoederkanker, darmkanker, leukemie, Hodgkin- 
en non-Hodgkin-lymfoom, en bot- en wekedelenkanker. Uit dit literatuuronderzoek bleek dat 
uitzaaiingen beperkt kunnen zijn tot een bepaald gebied in de buitenzijde van de eierstok. Dit 
impliceert dat de huidige tumordetectieprocedure niet nauwkeurig is door het te grote risico op 
een ‘sampling error’. 
Het onderzoek dat in hoofdstuk 2 wordt beschreven had tot doel om na te gaan hoe vaak 
uitzaaiingen in de eierstok voorkomen bij jonge vrouwen met borstkanker. Hiertoe werd een 
landelijk cohort samengesteld van alle vrouwen die op de leeftijd < 41 jaar zijn gediagnosticeerd 
met borstkanker in de periode 2000-2010 in Nederland en bij wie de eierstokken na de diagnose 
borstkanker zijn verwijderd. Uit dit onderzoek bleek dat bij 63 van de in totaal 2642 vrouwen die 
aan deze criteria voldeden (2.4%) bij histologisch onderzoek uitzaaiingen in de eierstok werden 
aangetroffen. Dit percentage is mogelijk een onderrapportage, omdat alleen vrouwen werden 
bestudeerd die in het kader van de behandeling eierstokverwijdering ondergingen. Desalniettemin 
is dit percentage het meest exacte dat tot nu toe bekend is en geeft het een goede indruk van de 
ordegrootte van het probleem. 
Daarnaast werden in dit onderzoek risicofactoren in kaart gebracht die een rol kunnen spelen 
bij de ontwikkeling van uitzaaiingen in de eierstok bij deze groep patiënten. Een opvallend 
verschil tussen de 63 cases en 2535 controles zonder uitzaaiingen in de eierstok in dit cohort 
was het tijdsinterval tussen de diagnose borstkanker en het verwijderen van de eierstok, namelijk 
respectievelijk 47.0 en 32.0 maanden (p = 0.002). Op basis van deze bevindingen concludeerden 
we dat het vroegtijdig verwijderen van de eierstok het risico op het ontwikkelen van uitzaaiingen in 
de eierstok aanzienlijk kan verminderen. Bovendien zou ons advies zijn om de eierstokfragmenten 
terug te plaatsen in de achtergebleven eierstok in plaats van, bijvoorbeeld, het buikvlies. Op deze 
manier bestaat de mogelijkheid om de eierstokfragmenten op een later tijdstip in het geheel te 
verwijderen, waardoor het risico op het ontwikkelen van uitzaaiingen in de eierstok eveneens 
kan worden verminderd. Multivariate logistische regressie analyses naar risicofactoren voor 
uitzaaiingen in de eierstokken werden verricht in een case-controle populatie die gematcht was 
op het tijdsinterval tussen de diagnose borstkanker en het verwijderen van de eierstokken. Deze 
analyses lieten zien dat het tumorstadium significant geassocieerd is met het ontwikkelen van 
uitzaaiingen in de eierstok (p = 0.024). Derhalve adviseren we een terughoudend beleid ten 
aanzien van het terugplaatsen van eierstokweefsel in jonge borstkankerpatiënten met tumoren 
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De eerste stap voor het ontwikkelen van tumor-specifieke NIRF-beeldvorming als nieuwe 
methode om uitzaaiingen in de eierstok te detecteren, is op zoek gaan naar eiwitten die 
specifiek tot expressie komen op de celmembraan van tumorcellen en afwezig zijn in het 
normale eierstokweefsel. Aangezien weefsel van borsttumoruitzaaiingen in de eierstok niet 
direct beschikbaar was in het LUMC hebben we in hoofdstuk 3 in eerste instantie een panel 
van acht membraaneiwitten onderzocht in invasieve borsttumoren. Deze borsttumoren waren 
afkomstig van borstkankerpatiënten die op grond van de inclusiecriteria zoals opgesteld door het 
Nederlands Netwerk Fertiliteitspreservatie (NNF) in aanmerking hadden kunnen komen voor het 
invriezen van eierstokweefsel. Op basis van dit onderzoek lijkt E-cadherine de meest geschikte 
marker voor de detectie van borsttumorcellen door middel van tumor-specifieke beeldvorming, 
aangezien E-cadherine op 94% van de invasieve borsttumorcellen in de 24 borsttumoren 
tot expressie kwam. In dit hoofdstuk hebben we tevens gekeken naar de expressie van deze 
markers in normaal eierstokweefsel van premenopauzale vrouwen. Geen van de acht geteste 
membraanmarkers kwam tot expressie in de stromacellen van het normale eierstokweefsel. Echter, 
alle markers, behalve CEA en uPAR, bleken aanwezig op epitheliale cellen van inclusiecysten. 
Dit zou betekenen dat een NIRF probe die gericht is tegen een van deze markers, niet alleen 
borsttumorcellen maar ook inclusiecysten zou doen oplichten. 
In hoofdstuk 4 hebben we de expressie van het bovengenoemde panel van membraaneiwitten 
onderzocht in borstkankeruitzaaiingen in de eierstok. Dit weefsel was afkomstig van het 
eerder beschreven cohort dat bestaat uit patiënten met borstkanker op de leeftijd < 41 jaar 
in de periode 2000-2010 in Nederland. Uit dit onderzoek bleek dat uitzaaiingen in de eierstok 
afkomstig van invasieve ductolobulaire borsttumoren met één marker, namelijk EMA, kunnen 
worden opgespoord. Voor het opsporen van uitzaaiingen in de eierstok van invasieve ductale 
borsttumoren waren drie markers nodig, namelijk E-cadherine, EMA en Her2/neu. Ook voor de 
detectie van uitzaaiingen in de eierstok van invasieve lobulaire borsttumoren was een combinatie 
van markers gewenst; de combinatie EMA, Her2/neu en EpCAM bleek hier het meest geschikt 
te zijn. 
Om te bepalen of de expressie van deze markers op de invasieve borsttumor kan voorspellen 
welke marker het meest geschikt is om de bijbehorende uitzaaiingen in de eierstok op te sporen, 
hebben we deze markers ook op de invasieve borsttumoren van deze patiënten onderzocht. 
Tussen de expressie van de markers op de invasieve borsttumoren en de bijbehorende uitzaaiingen 
in de eierstok kon geen correlatie worden aangetoond. Dit levert echter geen beperkingen op 
voor de klinische toepassing. De meest geschikte markercombinatie kan immers worden bepaald 
zodra de patholoog het histologische subtype van de invasieve borsttumor heeft vastgesteld.
Naar aanleiding van het literatuuronderzoek in hoofdstuk 1, hebben we in hoofdstuk 4 ook 
de lokalisatie en de vorm van de borsttumoruitzaaiingen in de eierstok onderzocht. Hieruit bleek 
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noduli die van elkaar worden onderscheiden door ‘normaal’ eierstokweefsel. Deze resultaten 
bevestigen de literatuurgegevens die werden beschreven in hoofdstuk 1. De bevindingen 
suggereren dat borsttumorcellen in de eierstok makkelijk kunnen worden gemist als de huidige 
tumordetectieprocedure zou worden toegepast. Er dient echter wel te worden vermeld dat de 
tijd tussen de diagnose borstkanker en het vaststellen van de uitzaaiingen in de eierstok in de 
patiënten in dit onderzoek gemiddeld 42 maanden was. Bij patiënten van wie eierstokweefsel 
daarentegen wordt ingevroren, wordt één van de eierstokken vlak na de diagnose borstkanker 
verwijderd. Het is derhalve aannemelijk dat uitzaaiingen in de eierstok van deze patiënten zich 
presenteren als micro-uitzaaiingen of losse tumorcellen. De kans dat deze uitzaaiingen worden 
gemist met de huidige tumordetectieprocedure lijkt derhalve nog groter. Aanvullend onderzoek 
is nodig om deze hypothese te bevestigen. 
Uit het onderzoek dat beschreven is in hoofdstuk 5 bleek dat FF-OCT uitzaaiingen in de 
eierstok zichtbaar kan maken. Bovendien bleek dat eicellen in verschillende ontwikkelingsstadia 
kunnen worden onderscheiden. Dit is gunstig, aangezien dit de mogelijkheid biedt om het 
aantal aanwezige rustende eicellen te bepalen. Dit aantal is sterk gerelateerd aan de kans 
op herstel van de eierstokfunctie. Met behulp van FF-OCT kunnen dus eierstokfragmenten 
worden geselecteerd die geen uitzaaiingen bevatten en bovendien een goede kans geven 
op herstel van de eierstokfunctie. Een kanttekening hierbij is dat uitzaaiingen en eicellen tot 
een weefseldiepte van maximaal 100 μm zichtbaar konden worden gemaakt. Deze beperkte 
weefselpenetratiediepte is zeer waarschijnlijk te wijten aan de grootschalige extracellulaire matrix 
in de eierstokfragmenten. De maximale weefseldiepte waarop uitzaaiingen en eicellen kunnen 
worden afgebeeld kan desalniettemin wel iets worden vergroot door de eierstokfragmenten van 
twee kanten te belichten. Bovendien is de verwachting dat het in de nabije toekomst mogelijk is 
om ook dieper gelegen structuren in de eierstokfragmenten af te beelden, aangezien FF-OCT sterk 
in ontwikkeling is. Een andere belangrijke bevinding van dit onderzoek was dat na kortdurende 
blootstelling aan FF-OCT de vitaliteit van zowel het eierstokweefsel als de eicellen behouden blijft. 
Ondanks het feit dat het ten gevolge van de beperkte weefselpenetratiediepte nog niet mogelijk 
is om alle uitzaaiingen en/of follikels met behulp van FF-OCT in de eierstok te detecteren, biedt 
FF-OCT een enorme verbetering ten opzichte van de huidige tumordetectietechnieken. FF-OCT 
is op dit moment immers de enige methode waarmee de eierstokfragmenten die daadwerkelijk 
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Toekomstperspectieven
In hoofdstuk 6 worden de bevindingen van dit proefschrift samengevat en in een breder perspec-
tief geplaatst. Tevens wordt ingegaan op de mogelijkheden voor toekomstig wetenschappelijk 
onderzoek. De haalbaarheid van NIRF-beeldvorming als nieuwe detectiemethode dient in eerste 
instantie in de preklinische setting te worden onderzocht. Hoewel het uiteindelijk noodzakelijk zal 
zijn om meerdere markers te combineren om alle borsttumorcellen in de eierstokken te kunnen 
detecteren, dienen deze studies zich in eerste instantie te richten op één tumor-specifieke probe om 
na te gaan of het principe werkt. Aangezien E-cadherine in 91% van de ductale borsttumorcellen 
in de eierstok tot expressie kwam (hoofdstuk 4) en de meerderheid van de borstkankerpatiënten 
gediagnosticeerd wordt met het ductale subtype, zou het zinvol zijn om een probe te ontwikkelen 
die specifiek gericht is tegen E-cadherine. Hiertoe kunnen antilichamen of peptiden tegen 
E-cadherine worden gebonden aan een fluorofoor die momenteel voor klinische toepassing 
beschikbaar is, bijvoorbeeld IRDye800CW (LI-COR Biosciences, Lincoln, NE) of ZW800-1 (The 
FLARE foundation, Wayland, MA). Daarnaast zouden antilichamen als trastuzumab (Herceptin; 
Genentech, San Francisco, CA) kunnen worden gelabeld aan IRDye 800CW om borsttumorcellen 
te detecteren die Her2/neu positief zijn. Dergelijke antilichamen hebben het voordeel dat zij reeds 
uitgebreid onderzocht en goedgekeurd zijn voor klinische toepassing. Nadat de bindingscapaciteit 
van de probes is vastgesteld, kunnen de probes in proefdieren worden getest. Voor dit doeleinde 
kunnen muizen worden gebruikt die geen afweersysteem hebben. In de eierstokken van deze 
muizen kunnen humane borsttumorcellen worden geïnjecteerd die positief zijn voor een van 
de markers waar tegen de tumor-specifieke NIRF-probe gericht is. Daarna kunnen de tumor-
specifieke NIRF-probes intraveneus aan de muis worden toegediend en kan de binding van 
deze probe aan de membraaneiwitten op de borsttumorcellen zichtbaar worden gemaakt door 
middel van multifotonmicroscopie of eventueel fotoakoestische beeldvorming. Fotoakoestische 
beeldvorming is een nieuwe beeldvormingstechniek die ultrageluidsgolven combineert met licht, 
waardoor het mogelijk is om nog dieper in het weefsel te kijken.
Wat betreft FF-OCT dient de sensitiviteit en specificiteit te worden vastgesteld waarmee 
uitzaaiingen in de eierstok gedetecteerd kunnen worden. Daarnaast dient de mogelijkheid om 
nakomelingen te produceren te worden geverifieerd. Om dit te bewerkstelligen kan eierstokweefsel 
van een muis dat al dan niet aan FF-OCT is blootgesteld, worden teruggeplaatst bij muizen zonder 
afweersysteem waarbij beide eierstokken verwijderd zijn. Vervolgens kan worden bestudeerd of 
eicelrijping optreedt en kunnen rijpe eicellen worden verkregen en bevrucht door middel van 
IVF. De muizenembryo’s kunnen tot slot worden teruggeplaatst in een draagmoedermuis. Indien 
dit succesvolle resultaten oplevert, kan FF-OCT als non-invasieve methode worden gebruikt om 
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Concluderend kan worden gesteld dat de huidige tumordetectieprocedure onvoldoende infor-
matie lijkt te kunnen geven over de aanwezigheid van borsttumorcellen in de eierstokfragmenten 
die daadwerkelijk worden teruggeplaatst. NIRF-beeldvorming en FF-OCT zijn veelbelovende 
alternatieve technieken om uitzaaiingen in eierstokweefsel te detecteren. Aangezien beide 
methoden in opzet non-invasief zijn, kunnen deze methoden mogelijk gecombineerd worden 
toegepast om de sensitiviteit en specificiteit te vergroten. Hoewel de studies in dit proefschrift 
voornamelijk gericht zijn op uitzaaiingen in de eierstok die afkomstig zijn van borstkanker, kan 
zowel NIRF-beeldvorming als FF-OCT naar verwachting ook worden gebruikt om uitzaaiingen op 
te sporen die afkomstig zijn van andere typen tumoren. Dit zou betekenen dat in de toekomst ook 
patiënten in aanmerking kunnen komen voor terugplaatsing van eierstokweefsel die momenteel 
worden uitgesloten vanwege een te hoog risico op herintroductie van tumorcellen. Dankzij 
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ALL    Acute lymphoblastic leukemia
AML    Acute myeloid leukemia
ASRM    American Society for Reproductive Medicine
AS101    Trichloro(dioxoethylene-O,O’) tellurate
BRCA    Breast cancer antigen 
CAM 5.2    Cytokeratin CAM 5.2
CCCN    Comprehensive Cancer Center the Netherlands
CCD    Charge-coupled device
CEA    Carcinoembryonic antigen
CI    Confidence interval
CK-7    Cytokeratin-7
CML    Chronic myeloid leukemia
CLL    Chronic lymphoblastic leukemia
DAB    Diaminobenzidine
DAPI    4’,6-diamidino-2-phenylindole
DMEM    Dulbecco’s modified eagle medium
EGFR    Epidermal growth factor receptor
EMA    Epithelial membrane antigen (MUC1; Mucin1)
EpCAM    Epithelial cell adhesion molecule
EPR    Enhanced penetration and retention
FCS    Fetal calf serum
FF-OCT    Full-field optical coherence tomography
FFPE    Formalin-fixed paraffin-embedded
FIGO    International Federation of Gynecology and Obstetrics
FMWV    Dutch Federation of Biomedical Scientific Societies
FR-α    Folate receptor alpha
GCDFP15   Gross cystic disease fluid protein-15
GFP    Green fluorescent protein
GnRH    Gonadotropin-releasing hormone
Her2/neu   Human epidermal growth factor receptor 2
H&E    Hematoxylin-and-eosin
Hz    Hertz
IgG1    Immunoglobulin G1
IgG2a    Immunoglobulin G2a
IVF    In vitro fertilization
LED    Light-emitting diode
LUMC    Leiden University Medical Center
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MRI    Magnetic resonance imaging
NIRF     Near-infrared fluorescence 
OCT    Optical coherence tomography
PAI    Photoacoustic imaging
PALGA    Dutch Pathology Registry
PBS    Phosphate buffered saline
PCR    Polymerase chain reaction
pH    Potential hydrogen
PT    Pre-treatment
Rpm    Revolutions per minute
SBR grade   Scarff-Bloom-Richardson grade
SCID    Severe combined immunodeficient 
SD    Standard deviation
SEER program    Surveillance, Epidemiology and End Results program
SISH    Silver in situ hybridization
SPSS    Statistical Package for the Social Sciences
S1P    Sphingosine-1-phosphate
TNM stage   Tumor/node/metastasis stage
TMA    Tissue microarray
uPAR    Urokinase-type plasminogen activator receptor
VEGF    Vascular endothelial growth factor
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Dit proefschrift is dankzij de steun van velen tot stand gekomen. Graag zou ik een aantal mensen 
in het bijzonder willen danken voor hun bijdragen:
Baptist Trimbos, veel dank voor je eeuwige support en je vermogen om mij het gevoel te geven 
dat alles altijd goed komt. Na een meeting met jou kon ik er weer vol tegenaan! 
Carina Hilders, jouw enorme bevlogenheid en onuitputtelijke dosis energie zijn waanzinnig en 
werken aanstekelijk! Voor mij ben jij het ultieme voorbeeld van hoe je door hard te werken je 
eigen koers kunt varen en je lang gekoesterde dromen daadwerkelijk kunt realiseren. 
Peter Kuppen, wat heb ik veel geleerd van je kritische blik op het schrijven van een wetenschappelijk 
artikel. En wat ben ik je dankbaar dat je je vanuit de Heelkunde zó ingezet hebt voor een 
proefschrift over fertiliteitspreservatie. Het feit dat je aan de wand in je werkkamer een afbeelding 
van een ovarium hebt hangen onderschrijft dit nog maar eens.
Alexander Vahrmeijer, onderzoek doen met jou is een feestje! Hard werken, maar minstens zo 
hard genieten. Veel dank voor je enorme toegankelijkheid en vertrouwen. 
Vincent Smit en Tjalling Bosse, veel dank dat ik te gast mocht zijn binnen de werkgroep 
Gynaecologische tumoren.
Kees Sier, een meeting met jou leverde vaak meer vragen dan antwoorden op. Hoewel ik je zelfs 
na het schrijven van dit proefschrift op enkele het antwoord schuldig moet blijven, heeft jouw 
kritische analytische blik mij zeker tot een betere onderzoeker gemaakt. Veel dank daarvoor.
Alle co-auteurs, veel dank voor jullie bijdrage aan de inhoud van dit proefschrift. Alle medewerkers 
van het Heelkunde Research lab en in het bijzonder Geeske Dekker-Ensink, Marieke Prevoo, Rob 
Keyzer en Ronald van Vlierberghe; zonder jullie had ik het nooit gered! Annelies van der Laan en 
Joop Wiegant, veel dank voor jullie bereidheid om keer op keer jullie medewerking te verlenen. 
Lucette van der Westerlaken en Gonneke Pilgram, veel dank voor jullie faciliterende rol in het IVF 
lab. Leoni Louwé, dank dat je er bent, wat is het fijn om met jou te sparren. 
Alle onderzoekers van de afdelingen Gynaecologie en Verloskunde, Heelkunde en Pathologie, 
met in het bijzonder de dames van P1-40. Keihard knallen onder het motto ‘Sciencing as fast as 
we can’, het was een onvergetelijke tijd!
Mijn studenten ‘dream team’ Daniëlle Krijgsman, Maria Fantaye, Merle van der Steen, Amber van 
der Zalm, Bertine Huisman en Florine Boer; wat heb ik veel van jullie geleerd en wat is het mooi 
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Marijke Hendriks-Van der Cingel en Xandra Bruin, veel dank voor jullie inzet en enthousiasme. 
Veel dank ook aan alle A(N)IOS, verloskundigen, verpleegkundigen en gynaecologen van het 
HagaZiekenhuis en LUMC, met in het bijzonder mijn opleiders Bart Hellebrekers en Jan van Lith. 
Ook veel dank aan mijn medebestuursleden van de SIG Fertiliteitspreservatie-NNF.
Familie en vrienden, jullie zijn goud waard! Wat een rijkdom om jullie zo dichtbij mij te hebben 
staan. 
Un ringraziamento speciale ai miei amici italiani. È con voi che è sorto il mio affetto profondo per 
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